WO2017134430A1 - Peptides de l'allegène du pollen du japon pour la prévention ou le traitement d'une allergie - Google Patents

Peptides de l'allegène du pollen du japon pour la prévention ou le traitement d'une allergie Download PDF

Info

Publication number
WO2017134430A1
WO2017134430A1 PCT/GB2017/050246 GB2017050246W WO2017134430A1 WO 2017134430 A1 WO2017134430 A1 WO 2017134430A1 GB 2017050246 W GB2017050246 W GB 2017050246W WO 2017134430 A1 WO2017134430 A1 WO 2017134430A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
amino acid
acid sequence
seq
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2017/050246
Other languages
English (en)
Inventor
Pascal Hickey
Paul Laidler
Dan GLIDDON
Jean-Francois Carniaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of WO2017134430A1 publication Critical patent/WO2017134430A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to polypeptides and pharmaceutical formulations thereof which may be used for preventing or treating allergy to Japanese Cedar and/or Japanese Cypress pollen.
  • Tree pollen allergens are recognised as a major cause of allergic diseases in humans.
  • allergy to pollen also known as pollinosis
  • the Japanese Cypress tree (Chamaecyparis obtusa, 'hinoki' in Japanese) also causes pollinosis in Japan.
  • the Japanese Cedar pollen season runs from February to March while the Japanese Cypress pollen season runs from March to April; symptoms can also persist beyond the pollen season.
  • a significant proportion of the Japanese population suffers from symptoms of pollinosis and allergy. Pollinosis and allergy also occur in other countries where the Japanese Cedar or Japanese Cypress trees is a native species or where the trees are cultivated, including Korea and China.
  • the invention provides a pharmaceutical formulation comprising:
  • RPTAIKIDYSKSVT SEQ ID NO: 5; CRY19A
  • T cell epitope-containing variant sequence derived from said amino acid sequence
  • GAYF VS SGK YEGG (SEQ ID NO: 163, CRY1 ID) or a T cell epitope-containing variant sequence derived from said amino acid sequence
  • TFKVDGIIAAYQNPASWK SEQ ID NO: 19; CRY15
  • a T cell epitope-containing variant sequence derived from said amino acid sequence wherein a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion;
  • each polypeptide is up to 30 amino acids in length;
  • each polypeptide may be present as a pharmaceutically acceptable salt thereof;
  • said pharmaceutical formulation further comprises a pharmaceutically acceptable carrier or diluent.
  • the invention also provides a polypeptide consisting of the amino acid sequence RPTAIKIDYSKSVT (SEQ ID NO: 5; CRY 19 A), KGAYF VS SGKYEGGK (SEQ ID NO: 165; CRY11F), TFK VEGII A A YQNP A S WK (SEQ ID NO: 54; CRY15A), KRIWLQFAKLTGFTLK (SEQ ID NO: 159; CRY 17 A), KSMKVTVAFNQFGP (SEQ ID NO: 13, CRY08), SKNFHLQKNTIGTG (SEQ ID NO: 166; CRY21C),
  • TYKNIRGTSAT SEQ ID NO: 23; CRY22
  • KDIKLSDISLKLTSGKIAS SEQ ID NO: 24; CRY23
  • a pharmaceutically acceptable salt thereof SEQ ID NO: 24; CRY23
  • the invention further provides a polypeptide, salt thereof or pharmaceutical formulation of the invention for use in a method of treating or preventing allergy to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • the invention further provides a method of treating an individual for allergy to Japanese Cedar pollen and/or Japanese Cypress pollen or of preventing in an individual allergy to Japanese Cedar pollen and/or Japanese Cypress pollen, which method comprises administering to said individual a therapeutically or prophylactically effective amount of a polypeptide, salt thereof or pharmaceutical formulation of the invention.
  • the invention also provides use of a polypeptide or salt thereof of the invention for the manufacture of a medicament for the prevention or treatment of allergy to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • the invention additionally provides an in vitro method of determining whether T cells recognize a polypeptide or salt thereof of the invention or a polypeptide or salt thereof of said pharmaceutical formulation of the invention comprising at least three polypeptides, which method comprises contacting said T cells with said polypeptide or salt thereof or said pharmaceutical formulation and detecting whether said T cells are stimulated by said polypeptide or salt thereof.
  • SEQ ID NOs 1 to 156 provide amino acid sequences as set out in Examples 1 to 9 and the Detailed Description of the Invention.
  • SEQ ID NOs 1, 114 to 116, 134, 135, 137, 138 correspond to amino acid sequences derived from Cry j IFR.
  • SEQ ID NOs 2, 6 to 15, 26, 29 to 32, 34 to 35, 37-38, 42, 48, 67 to 73, 140- 141, 148 , 150-151, 157-158 and 163-165 correspond to amino acid sequences derived from Cry j 1.
  • SEQ ID NOs 3 to 5, 16 to 22, 51, 54, 58, 60-62, 74-88, 142-145, 149, 159 to 162 and 166 correspond to amino acid sequences derived from Cry j2.
  • SEQ ID NOs 25 and 89-106 correspond to amino acid sequences derived from
  • SEQ ID NOs 107-113 correspond to amino acid sequences derived from Cry j chitinase.
  • SEQ ID NOs 27-28, 33, 36, 39-41, 43, 44, 46, 47, 49, 117-121 and 136 correspond to amino acid sequences derived from Cha ol .
  • SEQ ID NOs 50, 52, 53, 55-57, 59, 63-66, 122-133 , 146-147 and 167 correspond to amino acid sequences derived from Cha o2.
  • SEQ ID NOS: 154-156 correspond to amino acid sequences of control polypeptides used in Example 9.
  • Figure 1 shows the results of a cell proliferation assay using peptides described herein, and media (negative control), Candida Albicans and Japanese Cedar whole allergen extract (positive controls). Proliferation is measured as incorporation of 3H- thymidine (CPM - Y axis).
  • Figures 2 and 3 show the results of cell proliferation and cytokine release assays with peptides described herein. The percentage of subjects in the study population showing positive responses is shown, together with a ranking for peptides on each parameter.
  • the designation CHA19 used in Figures 2 and 3 (and also Figures 4-8) is an alternative reference for peptide CRY9A.
  • Figure 4 shows analyses of population coverage provided by preferred peptides based on cytokine release data shown in Figures 2 and 3.
  • Figure 4A shows the percentage of the study population responding to one, two or three peptides taken from the CRY11, CRY 15 and CRY 17 series. 98% of the study population responded to at least one of these peptides and 64% to all three peptides.
  • Figure 4B shows the percentage of the study population with a positive response to various preferred peptides for one, two or three of the cytokines (CK) analysed.
  • CK cytokines
  • Figure 5 A shows a heat map for responses across the subjects in the study population, with a result for a subject showing positive responses to a peptide for at least one cytokine shaded grey. Negative responses are shown as white. The response multiplicity score and cumulative cytokine response scores are also shown together with the total scores for the entire population for all eight peptides.
  • Figure 5B is identical to Figure 5 A save that positive responses are also shown alongside the number of cytokines for which a positive response was present (1, 2 or 3).
  • the response multiplicity score is the cumulative number of positive responses to each peptide for at least one cytokine..
  • the cumulative cytokine response score is the cumulative number of positive responses to each peptide for all three cytokines. Surrogate peptides from the CRY11, CRY17 and CRY21 series were used to represent responses for CRY1 IF, CRY17A and CRY21C.
  • Figures 6A and 6B show ULA binding analysis for various preferred peptides based on selected alleles present in the Japanese population.
  • Figure 6A shows potential impact in the Japanese population based on REVEAL® score for each peptide (as the percentage of the Japanese population which is covered).
  • Figure 6B shows potential impact in the Japanese Population based on stability index (as the percentage of the Japanese population which is covered). Calculation of the REVEAL® score and stability index and percentage impact in the Japanese population is described in
  • Figures 7 A to C provide detailed results for percentage impact in the Japanese population based on REVEAL® score for each peptide and each allele.
  • Figures 8A to 8C provide detailed results for percentage impact in the Japanese population based on stability index for each peptide and each allele.
  • Figure 9 shows individual and cumulative genotype frequencies for selected HLA alleles in the Japanese population.
  • the present invention is concerned with preventing or treating allergy to
  • Japanese Cedar pollen and/or Japanese Cypress pollen and provides polypeptides, and pharmaceutically acceptable salts thereof, suitable for this use. Said polypeptides or salts thereof may be provided in pharmaceutical formulations. Amino acid sequences and variant amino acid sequences
  • a polypeptide of the invention may for example comprise, consist or consist essentially of an amino acid sequence as shown in SEQ ID NO: 5.
  • a polypeptide of the invention may comprise, consist or consist essentially of a T cell epitope-containing variant sequence which is an amino acid sequence as shown in SEQ ID NO: 5 having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion.
  • a pharmaceutical composition of the invention may comprise a polypeptide that comprises, consists or consists essentially of an amino acid sequence as shown in SEQ ID NO: 163.
  • the polypeptide may comprise, consist or consist essentially of a T cell epitope-containing variant sequence which is an amino acid sequence as shown in SEQ ID NO: 163 having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion.
  • modifications in a variant sequence do not alter the functional properties of a T cell epitope present in the corresponding original amino acid sequence.
  • the functional properties of T cell epitopes are discussed further below.
  • sufficient contiguous amino acids of the corresponding original amino acid sequence are retained to contain a T cell epitope.
  • a variant sequence retains at least 8, preferably at least 9, contiguous amino acids of the original amino acid sequence.
  • the variant sequence may retain from 8 to 12 amino acids or from 9 to 12 amino acids of the original amino acid sequence.
  • the variant sequence may retain from 8 to 15 amino acids, or from 9 to 15 amino acids of the original amino acid sequence, such as at least 12 or at least 15 amino acids of the original amino acid sequence.
  • a variant sequence may have fewer than five amino acid modifications.
  • said variant sequence may have up to four amino acid modifications, more preferably up to three amino modifications, and most preferably only one or two amino acid modifications. All said modifications are independently a deletion, substitution or insertion.
  • the variant sequence has one or two amino acid modifications, the modification or each modification independently being a deletion or substitution.
  • a T cell epitope-containing variant sequence has an amino acid modification that is a deletion
  • the deleted amino acid is preferably removed from the N- or C-terminus of the corresponding original amino acid sequence. That is, the variant sequence is a truncation of the original amino acid sequence formed by removing one or more contiguous amino acids from the N- and/or C-terminus of the original sequence.
  • Such a variant sequence may optionally have no other deletions or no other modifications.
  • a deleted amino acid may less preferably be removed from an internal position in the corresponding original amino acid sequence.
  • removal from an internal position it is meant that a deleted amino acid is not itself at the N- or C-terminus of the original amino acid sequence and nor is it removed as part of a sequence of contiguous amino acids including the N- or C-terminus of the original amino acid sequence. That is, to be considered to be deletion from an internal position, said deletion must occur independently of deletion from the N- or C-terminus of the original amino acid sequence.
  • an example variant sequence having an internal deletion of two amino acids could be ADEFGH.
  • B and C are removed from internal positions and the original terminal residues A and H are retained.
  • a deletion of two contiguous amino acids from the N- terminus of the same original sequence would result in the variant sequence CDEFGH, in which A and B are removed and C is now at the N-terminus.
  • the deletion of B in this case is not a removal from an internal position, because it is removed as one of the two contiguous amino acids including the N-terminus of the original sequence.
  • the deleted amino acids may be removed from any combination of the N-terminus and/or the C-terminus and/or an internal position.
  • Preferred variant sequences have no more than one deletion from an internal position.
  • the deleted amino acids are removed from any combination of the N- and/or C-terminus of the original sequence. That is, the deleted amino acids may all be removed from the N-terminus of the original sequence, or they may all be removed from the C-terminus of the original sequence, or some amino acids may be removed from each end of the original sequence.
  • a variant sequence is an amino acid sequence of SEQ ID NO: 5 having one, two, three, four or five amino acids removed from the N-terminus of said sequence of SEQ ID NO: 5.
  • a variant sequence is an amino acid sequence of SEQ ID NO: 5 having one, two, three, four or five amino acids removed from the C-terminus of said sequence of SEQ ID NO: 5.
  • a variant amino acid sequence is an amino acid sequence of SEQ ID NO: 5 having a number of amino acids removed from both the N- and C-terminus of said sequence, provided that said sequence has no more than five modifications in total.
  • a preferred embodiment of such a variant sequence is an amino acid sequence of SEQ ID NO: 5 having one, two or three amino acids removed from the N- and/or C-terminus of said sequence of SEQ ID NO: 5, and optionally no other modifications.
  • variant amino acid sequences which have at least one deletion include:
  • KLTGFTLMGKGVIDGQ (SEQ ID NO : 151 ), which is the amino acid sequence of KLTGFTLMGKGVIDGQG (SEQ ID NO: 4) having one amino acid removed from the C-terminus.
  • T cell epitope-containing variant sequence has an amino acid modification that is a substitution
  • the substitution may occur at any position in the original amino acid sequence. It is preferred that said substitution does not introduce a proline or a cysteine. It is also preferred that said substitution is a conservative substitution.
  • amino acids with basic side chains such as lysine, arginine or histidine, may each be independently substituted for each other.
  • amino acids with acidic side chains such as aspartate and glutamate
  • a glutamate or glutamine may also preferably be replaced with pyroglutamate.
  • the amino acids with aliphatic side chains such as glycine, alanine, valine, leucine and isoleucine, may each be independently substituted for each other. Particularly preferred substitutions in this category are limited to the amino acids with smaller aliphatic side chains, that is glycine, alanine, valine, which may preferably each be independently substituted for each other.
  • substitutions include the substitution of methionine with norleucine (Nle).
  • a neutral amino acid may be substituted with another neutral amino acid
  • a charged amino acid may be substituted with another charged amino acid
  • a hydrophilic amino acid may be substituted with another hydrophilic amino acid
  • a hydrophobic amino acid may be substituted with another hydrophobic amino acid
  • a polar amino acid may be substituted with another polar amino acid
  • an aromatic amino acid may be substituted with another aromatic amino acid.
  • variant amino acid sequences which have at least one substitution include:
  • the variant sequence KIWLQFAQLTDFNL (SEQ ID NO: 57; Chal7), which is the amino acid sequence of RIWLQFAKLTGFTL (SEQ ID NO: 3; CRY 17) having four substitutions.
  • the amino acid R at position 1 of SEQ ID NO: 3 is substituted with lysine
  • the amino acid K at position 8 of SEQ ID NO: 3 is substituted with glutamine
  • the amino acid G at position 11 of SEQ ID NO: 3 is substituted with aspartate
  • the amino acid T at position 13 of SEQ ID NO: 3 is substituted with asparagine;
  • variant sequence KLTGFTLMGKGVIEGQK (SEQ ID NO: 58; Cry 18), which is the amino acid sequence of KLTGFTLMGKGVIDGQG (SEQ ID NO: 4) having two substitutions.
  • a polypeptide having the variant sequence of SEQ ID NO: 58 is particularly preferred for use according to the invention.
  • the amino acid D at position 14 of SEQ ID NO: 4 is substituted with glutamate, and the amino acid G at position 17 of SEQ ID NO: 4 is substituted with lysine;
  • the variant sequence QLTDFNLMGTGVIDGQG (SEQ ID NO: 59; Chal8), which is the amino acid sequence of KLTGFTLMGKGVIDGQG (SEQ ID NO: 4) having four substitutions.
  • the amino acid K at position 1 of SEQ ID NO: 4 is substituted with glutamine, the amino acid G at position 4 of SEQ ID NO: 4 is substituted with aspartate, the amino acid T at position 6 of SEQ ID NO: 4 is substituted with asparagine, and the amino acid K at position 10 of SEQ ID NO: 4 is substituted with threonine.
  • a variant sequence is the amino acid sequence of SEQ ID NO: 5 having a number of amino acids deleted from the N- and/or C-terminus of said sequence of SEQ ID NO: 5, and a number of substitutions provided that said sequence has no more than five modifications in total.
  • a preferred embodiment of such a variant sequence is the amino acid sequence of SEQ ID NO: 5 having one or two amino acids deleted at the N-and/or C-terminus of said sequence of SEQ ID NO: 5 and one or two substitutions made within the sequence of SEQ ID NO: 5.
  • the added amino acid may be inserted at any position in the original amino acid sequence. It is preferred that the insertion does not introduce a proline or a cysteine.
  • an amino acid may be inserted at the N-terminus and/or C-terminus of the original sequence. That is, the variant sequence is an extension of the original amino acid sequence formed by adding amino acids to the N- and/or C-terminus of the original sequence. Such a variant sequence may optionally have no other insertions or no other modifications.
  • an amino acid may be inserted at an internal position.
  • insertion at an internal position it is meant that an amino acid is inserted at any position which is C-terminal to the amino acid at the N-terminus of the original sequence, or that an amino acid is inserted at any position which is N-terminal to the amino acid at the C- terminus of the original sequence.
  • the added amino acids may be inserted at any combination of the N-terminus and/or the C-terminus and/or an internal position.
  • Preferred variant sequences have no more than one insertion at an internal position.
  • the added amino acids are inserted at any combination of the N- and/or C-terminus of the original sequence. That is, the added amino acids may all be inserted at the N-terminus of the original sequence, or they may all be inserted at the C-terminus of the original sequence, or some amino acids may be inserted at each end of the original sequence. That is, the added amino acids may be considered to extend the original sequence at the N- and/or C-terminus.
  • a variant sequence is the amino acid sequence of SEQ ID NO: 5 having one, two, three, four or five amino acids inserted at the N-terminus of said sequence of SEQ ID NO : 5.
  • a variant sequence is the amino acid sequence of SEQ ID NO: 5 having one, two, three, four or five amino acids inserted at the C-terminus of said sequence of SEQ ID NO: 5.
  • a variant sequence is the amino acid sequence of SEQ ID NO: 5 having a number of amino acids inserted at both the N- and C-terminus of said sequence of SEQ ID NO: 5, provided that said sequence has no more than five modifications in total.
  • a preferred embodiment of such a variant sequence is the amino acid sequence of SEQ ID NO: 5 having one, two or three amino acids inserted at the N- and/or C-terminus of said sequence of SEQ ID NO: 5, and optionally no other modifications.
  • a variant sequence having a charged amino acid inserted at the N- and/or C- terminus is particularly preferred where said charged amino acid will correspond to the N- and/or C-terminus of the polypeptide of the invention which comprises, consists or consists essentially of the variant sequence.
  • Charged residues at the N- and/or C- terminus of a polypeptide can improve the solubility of a polypeptide.
  • Preferred charged amino acids include lysine, arginine and histidine.
  • One, two or more amino acids selected from lysine, arginine and histidine may be added at the N- and/or C- terminus of the polypeptide. Lysine is particularly preferred.
  • a particularly preferred variant sequence is an amino acid sequence of SEQ ID NO: 5 having one or more charged amino acids, preferably one or more lysine residues, inserted at the N- and/or C-terminus of said sequence of SEQ ID NO: 5.
  • variant amino acid sequences which include addition of charged residues are:
  • variant sequences KVF YNGAYF VS SGKYEGG SEQ ID NO: 157; CRY1 IB
  • KVFYNGAYFVSSGKYEGGK SEQ ID NO: 158; CRY11C
  • variant sequences KRIWLQFAKLTGFTLK SEQ ID NO: 159; CRY 17 A
  • RIWLQFAKLTGFTLK SEQ ID NO: 160; CRY17B
  • CRY21 A which differs from the amino acid sequence of DIFASKNFHLQKNTIGT (SEQ ID NO: 22; CRY21) by the addition of N- and C-terminal lysine residues.
  • a variant sequence is the amino acid sequence of SEQ ID NO: 5 having a number of amino acids inserted at both the N- and C-terminus of said sequence of SEQ ID NO: 5, and a number of substitutions provided that said sequence has no more than five modifications in total.
  • a preferred embodiment of such a variant sequence is the amino acid sequence of SEQ ID NO: 5 having one or two amino acids inserted at the N-and/or C-terminus of said sequence of SEQ ID NO: 5 and one or two substitutions made within the sequence of SEQ ID NO: 5.
  • variant sequences there may be deletions and insertions.
  • variant sequence SKNFHLQKNTIGTGK (SEQ ID NO: 162; CRY21B) differs from the amino acid sequence of DIFASKNFHLQKNTIGT (SEQ ID NO: 22; CRY21) by the deletion of four N-terminal residues and the addition of C-terminal glycine and lysine residues.
  • the variant sequence SKNFHLQKNTIGTG (SEQ ID NO: 166; CRY21C) differs from the amino acid sequence of DIFASKNFHLQKNTIGT (SEQ ID NO:22; CRY21) by having four amino acids deleted from the N-terminus, and one amino acid deleted from the C-terminus, and the addition of a C-terminal glycine residue.
  • a polypeptide of the invention or a polypeptide provided in a pharmaceutical composition of the invention is up to 30 amino acids in length and comprises, consists or consists essentially of an amino acid sequence or variant sequence as defined above.
  • Said polypeptide may preferably be up to 25 amino acids in length, more preferably up to 20 amino acids in length or up to 17 amino acids in length, and most preferably up to 15 amino acids in length. Put another way, the polypeptide may have a maximum length of 30, 25, 20, 17 or 15 amino acids.
  • Said polypeptide is preferably at least 8 amino acids in length, more preferably at least 9 amino acids in length, most preferably at least 12 amino acids in length. Put another way, the polypeptide may have a minimum length of 8, 9, or 12 amino acids.
  • Said polypeptide may be of a length defined by any combination of a said minimum and a said maximum length.
  • the polypeptide may be 8 to 30, 8 to 25, 8 to 20, 8 to 17 or 8 to 15 amino acids in length.
  • the polypeptide may be 9 to 30, 9 to 25, 9 to 20, 9 to 17 or 9 to 15 amino acids in length.
  • the polypeptide may be 12 to 30, 12 to 25, 12 to 20, 12 to 17 or 12 to 15 amino acids in length.
  • a preferred polypeptide is of 9 to 30 amino acids in length, more preferably 9 to 20 amino acids in length.
  • a particularly preferred polypeptide is of 12 to 17 amino acids in length.
  • Said polypeptide may comprise an amino acid sequence or variant sequence as defined above. Therefore, said polypeptide may include additional amino acids which are not defined by said amino acid sequence or variant sequence. The additional amino acids may be described as flanking said amino acid sequence or variant sequence. That is, the additional amino acids are included at the N-terminus and/or C-terminus of said amino acid sequence or variant sequence.
  • said polypeptide may have a sequence consisting of said amino acid sequence or variant sequence having an N-terminal and/or C-terminal extension of a number of amino acids.
  • the maximum number of amino acids in the N-terminal and/or C-terminal extension is determined by the maximum length of the polypeptide, as defined above.
  • amino acids in an N-terminal extension of a said amino acid sequence or variant sequence preferably correspond to the amino acids immediately N-terminal to the said amino acid sequence in the native sequence of the protein from which it derives.
  • amino acids in a C-terminal extension of a said amino acid sequence or variant sequence preferably correspond to the amino acids immediately C-terminal to the said amino acid sequence in the native sequence of the protein from which it derives.
  • the N-terminal and/or C-terminal extension may be the one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding respectively to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N- terminal or C-terminal to said amino acid sequence in the sequence of the protein from which it derives.
  • the N-terminal and/or C-terminal extension is of from one to ten amino acids corresponding respectively to the one to ten contiguous amino acids immediately N-terminal or C-terminal to the said amino acid sequence in the native sequence of the protein from which it derives.
  • the N-terminal and/or C-terminal extension is of from one to six amino acids corresponding respectively to the one to six contiguous amino acids immediately N-terminal or C-terminal to the said amino acid sequence.
  • the N-terminal and/or C-terminal extension is of from one to four amino acids corresponding respectively to the one to four contiguous amino acids immediately N-terminal or C-terminal to the said amino acid sequence.
  • the N-terminal and/or C-terminal extension is of from one to two amino acids corresponding respectively to the one to two contiguous amino acids immediately N-terminal or C-terminal to the said amino acid sequence.
  • polypeptides which include an N-terminal and/or C- terminal extension to an amino acid sequence or variant sequence are provided below.
  • the N- and/or C-terminally extended polypeptides may be used in place of the corresponding original polypeptide in accordance with the invention.
  • SEQ ID NO: 1 include the following:
  • DLKIKLRRTIEAEGIP may have a N-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to DLKIKLRRTIEAEGIP in the native sequence of Cry IFR, that is the amino acids H, A, V, E, P, M, K, S, M and F.
  • the polypeptide of the invention has the amino acid sequence of H A VEPMK SMFDLKIKLRRTIE AEGIP (SEQ ID NO: 137; N-terminal extension underlined).
  • DLKIKLRRTIE AEGIP may have a C-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately C-terminal to DLKIKLRRTIEAEGIP in the native sequence of Cry IFR, that is the amino acids H, T, Y, V, V, P, H, C, F and A.
  • the polypeptide of the invention has the amino acid sequence of DLKIKLRRTIE AEGIPHTYVVPHCF A (SEQ ID NO: 138; C-terminal extension underlined).
  • DLKIKLRRTIEAEGIP may have a N-terminal extension of one, two, three, four, five, six, seven or eight amino acids corresponding to the one, two, three, four, five, six, seven or eight contiguous amino acids immediately N-terminal to DLKIKLRRTIEAEGIP in the native sequence of Cry IFR, that is the amino acids V, E, P, M, K, S, M and F. It may also have a C-terminal extension of one amino acid corresponding to the one contiguous amino acid immediately C-terminal to DLKIKLRRTIEAEGIP in the native sequence of Cry IFR, that is the amino acid H. For example, where all eight contiguous amino acids are present in the N-terminal extension and the one contiguous amino acid is present in the C-terminal extension, the polypeptide of the invention has the amino acid sequence of
  • VEPMK SMFDLKIKLRRTIE AEGIPH (SEQ ID NO: 114; N- and C-terminal extensions are underlined).
  • SEQ ID NO: 163 examples include the following:
  • GAYF VS SGKYEGG may have a N- terminal extension of one, two, three, four, five, six, seven, eight, nine, ten or more amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten or more contiguous amino acids immediately N-terminal to one, two, three, four, five, six, seven, eight, nine, ten or more contiguous amino acids immediately N-terminal to GAYFVS SGKYEGG in the native sequence of Cry j 1, that is the amino acids S, N, W, V, W, Q, S, T, Q, D, V, F, Y and N.
  • the polypeptide has the amino acid sequence of
  • GAYF VS SGKYEGG (CRY1 ID; SEQ ID NO: 163) may have a C- terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately C-terminal to GAYF VS SGKYEGG in the native sequence of Cry j 1, that is the amino acids N, I, Y, T, K, K, E, A, F and N.
  • the polypeptide has the amino acid sequence of GAYF VS SGKYEGGNI YTKKEAFN (SEQ ID NO: 141; C- terminal extension underlined).
  • SEQ ID NO: 3 examples include the following:
  • - RIWLQFAKLTGFTL may have a N-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to RIWLQFAKLTGFTL in the native sequence of Cry j2, that is the amino acids Y, Q, N, P, A, S, W, K, N and N.
  • the polypeptide has the amino acid sequence of YQNP ASWKNNRIWLQF AKLTGFTL (SEQ ID NO: 142; N- terminal extension underlined);
  • RIWLQFAKLTGFTL (SEQ ID NO: 3; CRY 17) may have a C-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately C-terminal to RIWLQFAKLTGFTL in the native sequence of Cry j2, that is the amino acids M, G, K, G, V, I, D, G, Q, and G.
  • the polypeptide has the amino acid sequence of RIWLQF AKLTGFTLMGKGVIDGQG (SEQ ID NO: 143; C-terminal extension underlined);
  • RIWLQFAKLTGFTL (SEQ ID NO: 3; CRY 17) may have an N-terminal extension of one amino acid corresponding to the one amino acid immediately N- terminal to RIWLQFAKLTGFTL in the native sequence of Cry j2, that is the amino acid N, and a C-terminal extension of one, two, three, four, five, six, seven, eight, or nine amino acids corresponding to the one, two, three, four, five, six, seven, eight, or nine contiguous amino acids immediately C-terminal to RIWLQFAKLTGFTL in the native sequence of Cry j2, that is the amino acids M, G, K, G, V, I, D, G, and Q.
  • the polypeptide has the amino acid sequence of NRIWLQF AKLTGFTLMGKGVIDGQ (SEQ ID NO: 77; N- and C-terminal extensions underlined);
  • SEQ ID NO: 4 examples include the following:
  • KLTGFTLMGKGVIDGQG may have a N-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to KLTGFTLMGKGVIDGQG in the native sequence of Cry j2, that is the amino acids K, N, N, R, I, W, L, Q, F and A.
  • the polypeptide has the amino acid sequence of KNNRIWLQF AKLTGFTLMGKGVIDGQG (SEQ ID NO: 144; N-terminal extension underlined).
  • - KLTGFTLMGKGVIDGQG may have a C-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately C-terminal to KLTGFTLMGKGVIDGQG in the native sequence of Cry j2, that is the amino acids.
  • the polypeptide has the amino acid sequence of
  • KLTGFTLMGKGVIDGQGKQWWAGQCKW (SEQ ID NO: 145; C-terminal extension underlined).
  • SEQ ID NO: 5 examples include the following:
  • RPTAIKIDYSKSVT (SEQ ID NO: 5; CRY 19 A) may have a N-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately N-terminal to RPTAIKIDYSKSVT in the native sequence of Cha o2, that is the amino acids N, G, R, T, V, C, N, D, R, and N.
  • the polypeptide of the invention has the amino acid sequence of NGRTVCNDRNRPT AD ID YSKS VT (SEQ ID NO: 146; N-terminal extension underlined).
  • RPTAIKIDYSKSVT (SEQ ID NO: 5; CRY 19 A) may have a C-terminal extension of one, two, three, four, five, six, seven, eight, nine or ten amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine or ten contiguous amino acids immediately C-terminal to RPTAIKIDYSKSVT in the native sequence of Cha o2, that is the amino acids V, K, E, L, T, L, M, N, S and P.
  • the polypeptide of the invention has the amino acid sequence of RPTAIKIDYSKSVT VKELTLMNSP (SEQ ID NO: 147; C- terminal extension underlined).
  • the amino acids in the N-terminal and/or C-terminal extension may not correspond exactly to amino acids in the native sequence of the protein from which the amino acid sequence or variant sequence derives.
  • the N-terminal and/or C-terminal extension may include a sequence derived from said native sequence which has been modified, for example to improve stability, solubility or manufacturability of the polypeptide.
  • a methionine in the native sequence may be substituted with nor-leucine, and/or one or more charged residues may be added at the N-terminus of an N-terminal extension and/or the C-terminus of a C-terminal extension.
  • Preferably positively charged residues such as arginine and lysine are added.
  • Amino acids selected from histidine, glutamate and aspartate may be added.
  • One, two or more amino acids selected from lysine, arginine and histidine may be added at the N- and/or C-terminus of the polypeptide.
  • amino acids of an N-terminal and/or C-terminal extension may not correspond to amino acids in native sequence of the protein from which the amino acid sequence or variant sequence derives. They may instead be any suitable amino acids, preferably selected to improve stability, solubility or manufacturability of the polypeptide.
  • one or more charged residues may be added at the N- and/or C-terminus of SEQ ID NO: 5. Preferably positively charged residues such as arginine and lysine are added. Amino acids selected from histidine, glutamate and aspartate may be added.
  • suitable polypeptides may have a sequence consisting of an N- or C-terminal extension of a said amino acid sequence of SEQ ID NOs 1, 3 to 25 and 163 which further comprises one or more deletions.
  • the polypeptide may comprise an extension of a said amino acid sequence within the native sequence at one terminus, such as the N-terminus, and a deletion of amino acids at the other terminus, such as the C-terminus.
  • the polypeptide may have a sequence consisting of an N-terminal extension of a said amino acid sequence with one, two, three, four, five, six, seven, eight, nine, ten or more amino acids corresponding respectively to the one, two, three, four, five, six, seven, eight, nine or ten or more contiguous amino acids immediately N- terminal to said amino acid sequence in the sequence of the protein from which it derives, and a deletion of one, two, three, four or five amino acids from the C-terminus of the said amino acid sequence.
  • the polypeptide may have a sequence consisting of a C-terminal extension of a said amino acid sequence with one, two, three, four, five, six, seven, eight, nine, ten or more amino acids corresponding respectively to the one, two, three, four, five, six, seven, eight, nine or ten or more contiguous amino acids immediately C-terminal to said amino acid sequence in the sequence of the protein from which it derives, and a deletion of one, two, three, four or five amino acids from the N-terminus of the said amino acid sequence.
  • polypeptides include the following:
  • GAYF VS SGKYEGG may have a N- terminal extension of one, two, three, four, five, six, seven, eight, nine, ten, eleven or more amino acids corresponding to the one, two, three, four, five, six, seven, eight, nine, ten, eleven or more contiguous amino acids immediately N-terminal to one, two, three, four, five, six, seven, eight, nine, ten, eleven or more contiguous amino acids immediately N-terminal to GAYFVSSGKYEGG in the native sequence of Cry j 1, that is the amino acids C, S, N, W, V, W, Q, S, T, Q D, F, W and N and one, two, three, four, or five deletions from the C-terminus.
  • the polypeptide has the amino acid sequence of CSNWVWQSTQDVFYNGAYFVSSG (SEQ ID NO: 148; N-terminal extension underlined).
  • the N- terminal Cysteine may further preferably be substituted with S, T, G, A or V.
  • - KLTGFTLMGKGVIDGQG may have a C-terminal extension of one, two, three, four, five, six, seven, or eight amino acids corresponding to the one, two, three, four, five, six, seven, or eight contiguous amino acids immediately C-terminal to KLTGFTLMGKGVIDGQG in the native sequence of Cry j2, that is the amino acids N, R, I, W, L, Q, F and A, and one deletion from the C-terminus.
  • the polypeptide of the invention has the amino acid sequence of
  • NRIWLQFAKLTGFTLMGKGVIDGQ (SEQ ID NO: 149; N-terminal extension underlined).
  • the invention provides a polypeptide of up to 30 amino acids in length and comprising, consisting essentially or consisting of the amino acid sequence of any one of SEQ ID NOs 3 to 25 and 163 or a corresponding variant sequence.
  • the invention preferably provides the polypeptide having the amino acid sequence KGAYFVSSGKYEGGK (SEQ ID NO: 165; CRYl lF), which is a variant of the amino acid sequence of SEQ ID NO: 163; CRY1 ID.
  • the invention also preferably provides the polypeptide having the amino acid sequence
  • KRIWLQF AKLTGFTLK (SEQ ID NO : 159; CRY17A), which is a variant of the amino acid sequence of SEQ ID NO: 3, CRY17.
  • the invention additionally preferably provides the polypeptide having the amino acid sequence TFKVEGIIAAYQNPASWK (SEQ ID NO: 54; CRY15A), which is a variant of the amino acid sequence of SEQ ID NO: 19; CRY15.
  • the invention also preferably provides the polypeptide having the amino acid sequence SKNFHLQKNTIGTG (SEQ ID NO: 166; CRY21C), which is a variant of the amino acid sequence of SEQ ID NO:22, CRY21 .
  • the invention also provides the polypeptide having the amino acid sequence S GNLNIKLKMPL YI AGYK (SEQ ID NO: 34; CRY04), which is a variant of SEQ ID NO: 9.
  • the invention further provides the polypeptide having the amino acid sequence SSNWVWQSTQDVF (SEQ ID NO: 45: CRY10A), which is a variant of SEQ ID NO: 15; CRY10.
  • the invention also provides the polypeptide having the amino acid sequence KLTGFTLMGKGVIEGQK (SEQ ID NO 58; CRY 18), which is a variant of the amino acid sequence of SEQ ID NO: 4.
  • variant sequences derived from the amino acid sequences of SEQ ID NOs 3 to 25 and 163 which are suitable for use according to the invention include:
  • SEQ ID NOs 48, 157, 158 and 164-165 which are variants of SEQ ID NO: 163.
  • SEQ ID NO 48 is an extension of the amino acid sequence of SEQ ID NO: 163 within the native sequence of the protein from which it derives, and additionally including an amino acid substitution.
  • SEQ ID NOs 157 and 158 are extensions of the amino acid sequence of SEQ ID NO: 163 within the native sequence of the protein from which it derives, and additionally including amino acid insertions.
  • SEQ ID NOs 164 and 165 are insertional variants of SEQ ID NO: 163.
  • SEQ ID NOs 29 and 32 which are variants of SEQ ID NO: 7.
  • SEQ ID NOs 29 and 31 are substitutional variants of SEQ ID NO: 7.
  • SEQ ID NO 30 is a deletional variant of SEQ ID NO: 7.
  • SEQ ID NO: 31 has deletions and substitutions with respect to SEQ ID NO: 7.
  • SEQ ID NOs 37 and 38 which are variants of SEQ ID NO: 11.
  • SEQ ID NO: 37 is an insertional variant of SEQ ID NO: 11, having a Lysine residue inserted both at the N-terminus and the C-terminus of SEQ ID NO: 11.
  • SEQ ID NO: 38 has a substitution with respect to SEQ ID NO: 37, i.e. has insertions and substitutions with respect to SEQ ID NO: 11.
  • SEQ ID NOs 54 and 55 which are variants of SEQ ID NO: 19.
  • SEQ ID NO: 54 is a substitutional variant of SEQ ID NO: 19.
  • SEQ ID NOs 64, 161 to 162 and 166 which are variants of SEQ ID NO: 22.
  • SEQ ID NO: 64 is a substitutional variant of SEQ ID NO:
  • SEQ ID NO: 161 is an insertional variant of SEQ ID NO: 22.
  • SEQ ID NOs: 162 and 166 include insertions and deletions with respect to SEQ ID NO: 22.
  • a polypeptide of the invention (or a polypeptide provided in a pharmaceutical composition of the invention) is up to 30 amino acids in length and comprises, consists or consists essentially of an amino acid sequence or variant sequence as defined above.
  • the amino acid sequence and each said variant sequence contains at least one T cell epitope.
  • the T cell epitope is preferably an MHC class II-binding T cell epitope.
  • sufficient contiguous amino acids of the corresponding original amino acid sequence are retained to contain a T cell epitope.
  • such a variant sequence retains at least 8, preferably at least 9, contiguous amino acids of the original amino acid sequence
  • T cell epitope may preferably be confirmed by analysis performed in silico, for example using bioinformatic software as described in Example 1. Alternatively, the presence of a T cell epitope may be confirmed by direct evaluation of its functional properties. Particular functional properties of T cell epitopes include the ability of a polypeptide comprising the epitope to bind to an MHC molecule, preferably an MHC class-II molecule, and/or the ability of a polypeptide comprising the epitope to activate a T cell, preferably when bound to an MHC Class II molecule.
  • the ability of a polypeptide to bind to an MHC molecule may be evaluated using any suitable method, such as a competition binding assay.
  • a competition binding assay Preferred in vitro binding assays are described in Examples 9 and 16.
  • a polypeptide to activate a T cell may also be evaluated using any suitable method.
  • Preferred methods include the measurement of one or more parameters associated with T cell activation, such as proliferation or cytokine release. Preferred assays for these parameters are described in Examples 10 and 15. Relevant cytokines include IFN-gamma, IL-13 and IL-10.
  • a polypeptide is typically considered to have activated a T cell if it induces release of one, two, or all of IFN-gamma, IL-13 and IL-10, such as release of both IFN-gamma and IL-13.
  • a positive proliferation or cytokine response is greater than the mean +/- 3* standard deviations of the background response (probability >99%).
  • the polypeptide may induce a release of greater than 50 pg/ml of the given cytokine(s), such as a release of greater than 100 pg/ml of the given cytokine(s).
  • a polypeptide comprising, consisting or consisting essentially of a variant amino acid sequence may have similar MHC class-II binding properties and/or similar T cell activation properties as a polypeptide comprising, consisting or consisting essentially of the corresponding original amino acid sequence.
  • a polypeptide has similar MHC class-II binding characteristics as another polypeptide if both polypeptides are capable of binding specifically to one or more MHC class-II molecules belonging to the same MHC class-II allele supertype family.
  • MHC class-II allele supertype families include HLA-DRl, HLA- DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DRl 1, HLA-DRl 3, HLA-DRl 5 and HLA-DR51. Both polypeptides may bind specifically to the same MHC class-II molecule, that is to an MHC class-II molecule encoded by the same allele.
  • a polypeptide has similar T cell activation properties as another polypeptide if both polypeptides specifically activate a T cell expressing the same T cell receptor.
  • the level of activation induced by each polypeptide may be similar. The level of activation may be assessed by monitoring proliferation and/or cytokine release, as described above.
  • Suitable polypeptides comprising, consisting or consisting essentially a variant sequence may be derived empirically or selected according to known criteria. Within a single polypeptide there are certain residues which contribute to binding within the MHC antigen binding groove and other residues which interact with hypervariable regions of the T cell receptor (Allen et al (1987) Nature 327: 713-5).
  • peptides may be designed to favour T-cell proliferation and induction of tolerance.
  • Metzler and Wraith have demonstrated improved tolerogenic capacity of polypeptides in which substitutions increasing polypeptide-MHC affinity have been made (Metzler & Wraith (1993) Int Immunol: 1159-65). That an altered polypeptide ligand can cause long-term and profound anergy in cloned T cells was demonstrated by Sloan-Lancaster et al (1993) Nature 363 : 156-9.
  • Suitable T cell epitope-containing variant sequences according to the invention may alternatively be described in terms of their sequence identity to a corresponding original amino acid sequence.
  • a variant sequence may have at least 65% identity to the amino acid sequence of SEQ ID NO: 5. More preferably, a variant sequence may have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% amino acid identity to an amino acid sequence of SEQ ID NO: 5.
  • Variants of the amino acid sequences of SEQ ID NOs 3, 4, 6 to 25 and 163 may also have the above levels of identity to their corresponding original amino acid sequence.
  • Sequence identity is typically evaluated over a number of contiguous amino acids in the original amino acid sequence. For example, sequence identity may be measured over at least 9, 10, 11, 12, 13, 14, or 15 contiguous amino acids in the original amino acid sequence, depending on the size of the peptides of comparison. It is preferred that sequence identity be measured over at least 9 contiguous amino acids in the original amino acid sequence. It is particularly preferred that sequence identity is measured over the entire length of the corresponding original amino acid sequence.
  • sequence identity refers to sequences which have the stated value when assessed using ClustalW (Thompson et al., 1994, supra) with the following parameters:
  • the invention encompasses any pharmaceutically acceptable salt of a polypeptide described herein.
  • Said pharmaceutically acceptable salts include, for example, mineral acid salts such as chlorides, hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, trifluoroacetates, propionates, malonates, benzoates, and the like; and salts of monocationic metal ions such as sodium and potassium and the like; and salts of bases such as ammonia.
  • a hydrochloride salt or an acetate salt is preferred.
  • polypeptide is polypeptide comprising the amino acid sequence of RPTAIKIDYSKSVT (SEQ ID NO: 5; CRY19A); or a T cell epitope-containing variant sequence derived from said amino acid sequence
  • a trifluoroacetate or hydrochloride salt thereof is preferred.
  • trifluoroacetate and hydrochloride salts of such a polypeptide have enhanced stability.
  • a hydrochloride salt is particularly preferred for pharmaceutical use and as having optimal stability.
  • polypeptides described herein can be prepared by any suitable technique.
  • Solid-phase peptide synthesis SPPS is a preferred technique. This involves formation of the peptide on small solid beads.
  • the peptide remains covalently attached to a bead during synthesis.
  • the peptide is synthesised using repeated cycles of coupling-washing-deprotection- washing.
  • the free N-terminal amine of a solid-phase attached peptide is coupled to a single N-protected amino acid unit. This unit is then deprotected, revealing a new N-terminal amine to which a further protected amino acid is attached. These steps are repeated until the peptide is complete.
  • the peptide is then cleaved from the beads using a suitable reagent. Suitable protecting groups, reagents, solvents and reaction conditions for SPPS are well known to those skilled in the art and as such conditions can be determined by one skilled in the art by routine optimization procedures.
  • compositions of polypeptides can be prepared by any suitable technique. Typically, salification involves reaction of the polypeptide or a salt thereof with a suitable reagent, typically acid, to obtain the pharmaceutically acceptable salt selected.
  • a suitable reagent typically acid
  • hydrochloride salt of a polypeptide can be prepared by initially cleaving the polypeptide from the solid phase using trifluoroacetic acid.
  • polypeptide will thus initially be a trifluoroacetate salt.
  • the trifluoroacetate salt can then be converted into a hydrochloride salt by any known technique, such as ion exchange on a suitable column using hydrochloric acid as an eluent.
  • polypeptide or polypeptide salt products can be purified, where required, by any suitable technique.
  • High pressure liquid chromatography HPLC can be used, for example.
  • polypeptide includes not only molecules in which amino acid residues are joined by peptide (-CO- H-) linkages but also molecules in which the peptide bond is reversed.
  • Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Meziere et al (1997) J. Immunol.159, 3230-3237. This approach involves making pseudopolypeptides containing changes involving the backbone, and not the orientation of side chains.
  • the peptide bond may be dispensed with altogether provided that an appropriate linker moiety which retains the spacing between the carbon atoms of the amino acid residues is used; it is particularly preferred if the linker moiety has substantially the same charge distribution and substantially the same planarity as a peptide bond.
  • the peptide may conveniently be blocked at its N-or C-terminus so as to help reduce susceptibility to exoproteolytic digestion.
  • the N-terminal amino group of the polypeptides may be protected by reacting with a carboxylic acid and the C-terminal carboxyl group of the peptide may be protected by reacting with an amine.
  • modifications include glycosylation and phosphorylation.
  • Another potential modification is that hydrogens on the side chain amines of R or K may be replaced with methylene groups (- H 2 — » - H(Me) or -N(Me) 2 ).
  • Analogues of polypeptides according to the invention may also include peptide variants that increase or decrease the polypeptide's half-life in vivo.
  • analogues capable of increasing the half-life of polypeptides used according to the invention include peptoid analogues of the peptides, D-amino acid derivatives of the peptides, and peptide-peptoid hybrids.
  • peptoid analogues of the peptides include peptoid analogues of the peptides, D-amino acid derivatives of the peptides, and peptide-peptoid hybrids.
  • polypeptides used according to the invention comprises D-amino acid forms of the polypeptide.
  • the preparation of polypeptides using D-amino acids rather than L-amino acids greatly decreases any unwanted breakdown of such an agent by normal metabolic processes, decreasing the amounts of agent which needs to be administered, along with the frequency of its administration.
  • polypeptides provided by the present invention may be derived from splice variants of the parent proteins encoded by mRNA generated by alternative splicing of the primary transcripts encoding the parent protein chains.
  • the polypeptides may also be derived from amino acid mutants, glycosylation variants and other covalent derivatives of the parent allergen proteins.
  • Exemplary derivatives include molecules wherein the polypeptides of the invention are covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid. Further included are naturally occurring variant amino acid sequences of the parent proteins. Such a variant amino acid sequence may be encoded by an allelic variant or represent an alternative splicing variant.
  • Modifications as described above may be prepared during synthesis of the peptide or by post-production modification, or when the polypeptide is in recombinant form using the known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids.
  • polypeptides described herein may also be modified to improve
  • original amino acid sequences may be altered to improve their solubility, and accordingly a polypeptide of the invention having a variant sequence will preferably be more soluble than a polypeptide having the corresponding original amino acid sequence under equivalent conditions.
  • Methods for evaluating the solubility of polypeptides are well known in the art. Improved solubility is advantageous for the tolerisation of subjects to the allergen from which the polypeptide derives, since administration of poorly soluble agents to subjects causes undesirable, non-tolerising inflammatory responses.
  • the solubility of the polypeptides may be improved by altering the residues which flank the region containing a T cell epitope.
  • N- and C-terminal to the residues of the polypeptide which flank a T cell epitope at least one amino acid may be added selected from arginine, lysine, histidine, glutamate and aspartate.
  • any hydrophobic residues in the up to three amino acids at the N- or C- terminus of the native sequence of the polypeptide, which are not comprised in a T cell epitope, are deleted; and/or
  • any two consecutive amino acids comprising the sequence Asp-Gly in the up to four amino acids at the N- or C-terminus of the native sequence of the polypeptide, which are not comprised in a T cell epitope, are deleted;
  • one or more positively charged residues are added at the N and/or C terminus of the native sequence of the polypeptide.
  • any polypeptides containing cysteine residues may be engineered to prevent dimer formation such that any cysteine residues are replaced with serine or 2- aminobutyric acid.
  • the invention provides combinations of polypeptides and salts thereof including combinations of at least three polypeptides or salts thereof.
  • Such a combination of polypeptides or salts thereof is preferably provided in a pharmaceutical formulation as described below.
  • Each polypeptide in the combination of polypeptides is up to 30 amino acids in length.
  • a typical combination of polypeptides of the invention comprises at least:
  • RPTAIKIDYSKSVT SEQ ID NO: 5; CRY 19 A
  • T cell epitope-containing variant sequence derived from said amino acid sequence
  • GAYF VS SGK YEGG (SEQ ID NO: 163, CRY1 ID) or a T cell epitope-containing variant sequence derived from said amino acid sequence
  • a polypeptide comprising the amino acid sequence of TFKVDGIIAAYQ PASWK (SEQ ID NO: 19; CRY15) or a T cell epitope-containing variant sequence derived from said amino acid sequence
  • a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion, wherein each polypeptide is up to 30 amino acids in length; and wherein each polypeptide may be present as a pharmaceutically acceptable salt thereof.
  • the invention provides a pharmaceutical formulation comprising the above polypeptides of (a) to (c) or salts thereof, and a pharmaceutically acceptable carrier or diluent.
  • the polypeptide of (a) may be present as a trifluoroacetate salt or hydrochloride salt thereof.
  • the polypeptide of (a) is preferably present as a hydrochloride salt thereof.
  • polypeptide CRY1 ID of (b) is preferably replaced by a polypeptide having the corresponding variant sequence KGAYF VS SGKYEGGK (SEQ ID NO: 165; CRY11F) or a salt thereof.
  • polypeptide CRY15 of (c) is also preferably replaced by a polypeptide having the corresponding variant sequence TFKVEGIIAAYQNPASWK (SEQ ID NO: 54;
  • the pharmaceutical formulation comprises at least one polypeptide or salt thereof selected from:
  • polypeptide comprising, consisting essentially of or consisting of the amino acid sequence RPTAIKIDYSKSVT (SEQ ID NO: 5; CRY19A or a said salt thereof,
  • polypeptide comprising, consisting essentially of or consisting of the amino acid sequence KGAYF VS SGKYEGGK (SEQ ID NO: 165; CRY11F) or a said salt thereof, and
  • (cl) a polypeptide comprising, consisting essentially of or consisting of the amino acid sequence TFKVEGIIAAYQNPASWK (SEQ ID NO: 54; CRY 15 A) or a said salt thereof.
  • the pharmaceutical formulation of at least three polypeptides may preferably comprise two polypeptides or salts thereof selected from (al) and (bl), (bl) and (cl) and (al) and (cl) above, or all three of the polypeptides or salts thereof of (al), (bl) and (cl).
  • a pharmaceutical formulation of the invention may preferably comprise the polypeptides CRYl 9 A and CRYl IF or salts thereof; the polypeptides CRYl 9 A and CRYl 5 A or salts thereof; the polypeptides CRYl IF and CRYl 5 A; or more preferably the polypeptides CRY 19 A, CRYl IF and CRYl 5 A or salts thereof.
  • polypeptide of (d) a polypeptide of (e)
  • polypeptide of (e) a polypeptide of (e)
  • RIWLQFAKLTGFTL SEQ ID NO: 3; CRY 17
  • T cell epitope-containing variant sequence derived from said amino acid sequence
  • KSMKVTVAFNQFGP SEQ ID NO: 13, CRY08
  • T cell epitope-containing variant sequence derived from said amino acid sequence
  • T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion;
  • polypeptide is up to 30 amino acids in length
  • polypeptide may be present as a pharmaceutically acceptable salt thereof.
  • a pharmaceutical formulation of the invention may comprise four polypeptides or salts thereof selected from (a), (b), (c) and (d); or (a), (b), (c) and (e).
  • the polypeptide CRYl 7 of (d) is preferably replaced by a polypeptide having the corresponding variant sequence KRIWLQFAKLTGFTLK (SEQ ID NO: 159; CRY17A) or a said salt thereof.
  • pharmaceutical formulations comprising polypeptides or salts thereof of (d) and/or (e) comprise at least one polypeptide or salt thereof selected from:
  • polypeptide comprising, consisting essentially of or consisting of the amino acid sequence KSMKVTVAFNQFGP (SEQ ID NO: 13, CRY08) or a said salt thereof.
  • the pharmaceutical formulation may preferably comprise polypeptides or salts thereof selected from (al), (bl), (cl), and (dl) above; or (al), (bl), (cl) and (el) above. More preferably the pharmaceutical formulation comprises all five polypeptides or salts thereof of (a) to (e), such as all five polypeptides of (al) to (el). It is particularly preferred that the pharmaceutical formulation comprises the five polypeptides
  • polypeptide of (f) a polypeptide of (f); and/or a polypeptide of (g).
  • DIFASKNFHLQKNTIGT (SEQ ID NO: 22; CRY21) or a T cell epitope-containing variant sequence derived from said amino acid sequence, and
  • T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion;
  • each selected polypeptide is up to 30 amino acids in length; and wherein each selected polypeptide may be present as a pharmaceutically acceptable salt thereof.
  • polypeptide CRY21 of (f) is preferably replaced by a polypeptide having the corresponding variant sequence
  • compositions comprising polypeptides or salts thereof of (f) and/or (g) comprise at least one polypeptide or salt thereof selected from:
  • polypeptide comprising, consisting essentially of or consisting of the amino acid sequence SKNFHLQKNTIGTG (SEQ ID NO: 166; CRY21C) or a said salt thereof, and
  • polypeptide comprising, consisting essentially of or consisting of the amino acid sequence TYKNIRGTSAT (SEQ ID NO: 23; CRY22) or a said salt thereof.
  • a pharmaceutical formulation of the invention may comprise polypeptides or salts thereof selected from (a), (b), (c) and (f); or (a), (b), (c) and (g).
  • pharmaceutical formulation may comprise four or five polypeptides or salts thereof selected in one of the following combinations: (a), (b), (c), (d) and (f); (a), (b), (c), (e) and (f); (a), (b), (c), (d) and (g); (a), (b), (c), (e) and (g); or (a), (b), (c), (f) and (g). More preferably, the pharmaceutical formulation may comprise each of the polypeptides or salts thereof of (a) to (g). In each of the above polypeptide combinations, polypeptides of (al), (bl), (cl), (dl), (el), (fl) and (gl) are preferably included where applicable.
  • KDIKLSDISLKLTSGKIAS (CRY23; SEQ ID NO: 24), or a T cell epitope- containing variant sequence derived from said amino acid sequence
  • T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion;
  • polypeptide is up to 30 amino acids in length
  • polypeptide may be present as a pharmaceutically acceptable salt thereof.
  • polypeptide of (h) or salt thereof is:
  • polypeptide comprising, consisting essentially of or consisting of the amino acid sequence KDIKLSDISLKLTSGKIAS (CRY23; SEQ ID NO: 24) or a said salt thereof.
  • a pharmaceutical formulation of the invention may thus comprise four, five or six polypeptides or salts thereof selected in one of the following combinations: (a), (b), (c), (d) and (h); (a), (b), (c), (e) and (h); (a), (b), (c), (f) and (h); (a), (b), (c), (g) and (h); (a), (b), (c), (e), (f) and (h); (a), (b), (c), (e), (f) and (h); (a), (b), (c), (e), (g) and (h); (a), (b), (c), (d), (e), and (h); (a), (b), (c), (d), (f) and (h); (a), (b), (c), (d), (g) and (h).
  • polypeptides of (al), (bl), (cl), (dl), (el), (fl), (gl) and (h) are preferably included where applicable.
  • Particularly preferred combinations include seven polypeptides or salts thereof selected from the polypeptides of (a) to (h) or salts thereof.
  • a combination may include the polypeptides of (a), (b), (c), (d), (f), (g) and (h) or salts thereof.
  • a pharmaceutical formulation of the invention comprises the polypeptides of (a) to (g) or salts thereof, the polypeptides of (a) to (f) and (h) or salts thereof, or the polypeptides of (a) to (e), (g) and (h) or salts thereof.
  • Especially preferred seven polypeptide combinations are:
  • TFKVEGIIAAYQNPASWK (SEQ ID NO: 54; CRY 15 A) or a salt thereof;
  • polypeptide having the amino acid sequence KRIWLQFAKLTGFTLK (SEQ ID NO: 159; CRY 17 A) or a salt thereof;
  • polypeptide having the amino acid sequence KSMKVTVAFNQFGP (SEQ ID NO: 13, CRY08) or a salt thereof;
  • polypeptide having the amino acid sequence SKNFULQKNTIGTG (SEQ ID NO: 166; CRY21C) or a salt thereof;
  • polypeptide having the amino acid sequence TYKNIRGTSAT (SEQ ID NO: 23; CRY22) or a salt thereof;
  • TFKVEGIIAAYQNPASWK (SEQ ID NO: 54; CRY 15 A) or a salt thereof;
  • polypeptide having the amino acid sequence KRIWLQFAKLTGFTLK (SEQ ID NO: 159; CRY 17 A) or a salt thereof;
  • polypeptide having the amino acid sequence KSMKVTVAFNQFGP (SEQ ID NO: 13, CRY08) or a salt thereof;
  • KDIKLSDISLKLTSGKIAS (CRY23; SEQ ID NO: 24) or a salt thereof
  • TFKVEGIIAAYQNPASWK (SEQ ID NO: 54; CRY 15 A) or a salt thereof;
  • polypeptide having the amino acid sequence KSMKVTVAFNQFGP (SEQ ID NO: 13, CRY08) or a salt thereof;
  • polypeptide having the amino acid sequence TYKNIRGTSAT (SEQ ID NO : 23 ; CRY22) or a salt thereof;
  • KDIKLSDISLKLTSGKIAS (CRY23; SEQ ID NO: 24) or a salt thereof.
  • the pharmaceutical formulation comprises each of the polypeptides of (a) to (h) or salts thereof, which are preferably polypeptides of (a 1) to (hi) or salts thereof.
  • the most preferred combination of eight such polypeptides is the combination of:
  • TFKVEGIIAAYQNPASWK (SEQ ID NO: 54; CRY 15 A) or a salt thereof;
  • polypeptide having the amino acid sequence KRIWLQFAKLTGFTLK (SEQ ID NO: 159; CRY 17 A) or a salt thereof;
  • polypeptide having the amino acid sequence SKNFULQKNTIGTG (SEQ ID NO: 166; CRY21C) or a salt thereof; a polypeptide having the amino acid sequence TYKNIRGTSAT (SEQ ID NO: 23; CRY22) or a salt thereof; and
  • KDIKLSDISLKLTSGKIAS (CRY23; SEQ ID NO: 24) or a salt thereof.
  • polypeptide combinations of the invention are selected from one or more of:
  • KLTGFTLMGKGVIDGQG SEQ ID NO: 4
  • T cell epitope-containing variant sequence derived from said amino acid sequence
  • KKFVVNNLFFNGP (SEQ ID NO: 18; Cry 14) or a T cell epitope-containing variant sequence derived from said amino acid sequence
  • CSNWVWQSTQDVF (SEQ ID NO: 15; Cry 10) or a T cell epitope-containing variant sequence derived from said amino acid sequence, and
  • SWKNNRIWLQFA SEQ ID NO: 20; Cry 16 or a T cell epitope-containing variant sequence derived from said amino acid sequence
  • T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to five amino acid modifications, each of which is independently a deletion, substitution or insertion;
  • each polypeptide is up to 30 amino acids in length;
  • each polypeptide may be present as a pharmaceutically acceptable salt thereof.
  • a polypeptide combination of the invention may comprise one, two, three, or four polypeptides selected from (i) to (1) or salts thereof.
  • One or more polypeptides of (i) to (1) or salts thereof may be included as additional polypeptides in a pharmaceutical formulation of the invention alongside any polypeptide combination comprising polypeptides (a) to (c) or salts thereof described above.
  • a polypeptide of (i) or a salt thereof may be added to a polypeptide combination comprising polypeptides of (a), (b), (c), (d), (f), (g) and (h) or salts thereof.
  • one or more polypeptides of (i) to (1) or salts thereof may replace a corresponding number of polypeptides selected from (d) to (h) or salts thereof in a polypeptide combination described above.
  • the polypeptide (h) or a salt thereof may be replaced with a polypeptide of any of (i) to (1) or a salt thereof in any polypeptide combination comprising a polypeptide of (h) or a salt thereof described above.
  • polypeptide combination comprising a polypeptide having the amino acid sequence of (i)
  • said polypeptide or salt thereof is preferably replaced with a
  • polypeptide having its corresponding variant sequence KLTGFTLMGKGVIEGQK (SEQ ID NO: 58; Cryl8) or a salt thereof.
  • said polypeptide or salt thereof is preferably replaced with a polypeptide having its corresponding variant sequence SSNWVWQSTQDVF (SEQ ID NO: 45; CRY10A) or a salt thereof.
  • polypeptide combinations may be suitable for use in preventing or treating allergy to Japanese Cedar pollen and/or Japanese Cypress pollen, for example since a polypeptide of (a) comprising the amino acid sequence RPTAIKIDYSKSVT (SEQ ID NO: 5; CRY19A) or a corresponding variant sequence represents an epitope region which is homologous between pollen allergens from both trees (Cry j 1 and Cha o 1).
  • the invention thus provides polypeptide combinations which are suitable for tolerisation against both Japanese Cedar pollen and/or Japanese Cypress pollen allergens by virtue of representing epitope regions which are homologous between pollen allergens from both trees.
  • All of the above selections are subject to the combination preferably comprising twelve polypeptides in total or less, more typically, ten polypeptides or less, preferably less than nine, more preferably eight or less polypeptides.
  • the combination may comprise four, five, six or seven polypeptides.
  • the combination of the invention preferably comprises seven or more preferably eight polypeptides.
  • polypeptide combinations described above may optionally comprise no further polypeptides or no further peptides derived from Japanese Cedar and/or Japanese Cypress allergens. Any of the polypeptide combinations described above may be incorporated in a pharmaceutical formulation of the invention as described in more detail below.
  • the polypeptides, salts thereof and pharmaceutical formulations of the invention are used for treating or preventing allergy to Japanese Cedar pollen and/or Japanese Cypress pollen. They preferably treat allergy to Japanese Cedar pollen. They may prevent or treat the allergy by inducing immune tolerance to subsequent exposure to allergen.
  • the tolerisation may be to one or more protein allergens of the Cryptomeria and/or Chamaecyparis genus.
  • the tolerisation is typically to protein allergens from Cryptomeria japonica and/or Chamaecyparis obtusa.
  • a method of treating an individual for allergy to Japanese Cedar pollen and/or Japanese Cypress pollen or of preventing in an individual allergy to Japanese Cedar pollen and/or Japanese Cypress pollen comprises administering to said individual a therapeutically or prophylactically effective amount of a polypeptide or salt thereof of the invention or of a pharmaceutical formulation of the invention.
  • the method may thus reduce or ameliorate the symptoms of allergy in the individual suffering from the allergy.
  • the method may improve the condition of the individual suffering from the allergy.
  • the method may prevent or delay the appearance of symptoms of allergy in the individual. Symptoms of allergy to Japanese Cedar pollen and/or Japanese Cypress pollen are discussed below.
  • a combination of polypeptides or salts thereof can be used for treating or preventing allergy to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • the polypeptides and/or salts thereof in a combination need not be administered together, and/or need not be part of the same pharmaceutical formulation.
  • the invention thus provides a polypeptide or salt thereof of the invention for use in a method of preventing or treating allergy to Japanese Cedar pollen and/or Japanese Cypress pollen as described above, wherein said method further comprises
  • the multiple polypeptides of this method may each be administered simultaneously, sequentially or concurrently. Thus, they may be administered separately.
  • the polypeptides, salts thereof and pharmaceutical formulations of the invention may treat or prevent the allergy by inducing immune tolerance to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • a polypeptide or salt thereof described herein may be used to tolerise or desensitise an individual to the allergen from which it is derived. Desensitising an individual to the allergens means inhibition or dampening of allergic tissue reactions induced by the allergens in appropriately sensitised individuals.
  • the term "tolerisation” refers to an ability to suppress, or abolish a response to an antigen, such as an allergic response to a protein allergen. Tolerisation is also an ability to diminish or abolish an unwanted immune response to a protein allergen. Tolerisation may be determined by in vitro analysis of T cell responses or by observation of a reduction in the symptoms in an individual.
  • T cells can be selectively activated, and then rendered
  • the tolerisation manifests itself as a reduction in response to an allergen or allergen-derived peptide, or preferably an elimination of such a response, on second and further administrations of the allergen or allergen-derived peptide.
  • This second administration may be made after a suitable period of time has elapsed to allow tolerisation to occur; this is preferably any period between one day and several weeks. An interval of around four weeks is preferred.
  • the individual to whom the polypeptide, salt thereof or pharmaceutical formulation is administered may be asymptomatic.
  • a prophylactically effective amount of the polypeptide or pharmaceutical formulation is administered to such an individual.
  • a prophylactically effective amount is an amount which prevents the onset of one or more symptoms of allergy.
  • the individual to whom the polypeptide, salt thereof or pharmaceutical formulation is administered may be in need thereof. That is, the individual may exhibit one or more symptoms of allergy.
  • a therapeutically effective amount of the polypeptide or pharmaceutical formulation is administered to such an individual.
  • a therapeutically effective amount is an amount which is effective to ameliorate one or more symptoms of allergy.
  • the individual to whom the polypeptide, salt thereof or pharmaceutical formulation is administered is preferably human.
  • the individual may be known to be sensitised to Japanese Cedar pollen and/or Japanese Cypress pollen allergens, at risk of being sensitised or suspected of being sensitised.
  • the individual can be tested for sensitisation using techniques well known in the art and as described herein.
  • the individual may have a family history of allergy to Japanese Cedar pollen and/or Japanese Cypress pollen. It may not be necessary to test an individual for sensitisation to Japanese Cedar pollen and/or Japanese Cypress pollen because the individual may display symptoms of allergy when exposed to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • exposure is meant proximity to, for example, a tree or pollen or a substance or product derived from a tree or pollen. By proximity is meant 10 metres or less, 5 metres or less, 2 metres or less, 1 metre or less, or 0 metres from the items described above.
  • Symptoms of allergy can include an itching nose, sneezing, ocular tearing, an itchy throat, itchy palate, itchy eyes, runny nose, breathing difficulties, bronchospasm, asthma, red itchy skin or rash.
  • the individual may be of any age. However, preferably, the individual may be in the age group of 1 to 90, 5 to 60, 10 to 40, or more preferably 18 to 35.
  • the individual may have had allergy to Japanese Cedar pollen and/or Japanese Cypress pollen for at least 2 weeks, 1 month, 6 months, 1 year, 5 years or more than 5 years.
  • the individual may suffer from a rash, nasal congestion, nasal discharge and/or coughing caused by the allergy.
  • the individual may suffer from an itching nose, sneezing, ocular itching, ocular tearing, itchy throat, itchy palate, bronchospasm and/or asthma caused by the allergy.
  • the individual may or may not have been administered with other items.
  • compositions/compounds which treat Japanese Cedar pollen and/or Japanese Cypress pollen allergy The individual may live in a geographical region which has a temperate, semi-tropical, or tropical climate. The individual typically suffers from allergy to Japanese Cedar pollen and/or Japanese Cypress pollen in a particular season but the allergy may be perennial. Seasonal allergy to Japanese Cedar pollen and/or Japanese Cypress pollen may commonly occur either in late Winter or in Spring in the Far East.
  • the allergic individual is allergic to tree pollen from the Japanese Cedar and/or
  • the allergic individual is preferably allergic to tree pollen from the Japanese Cedar tree.
  • the allergic individual may be allergic both to tree pollens of Cryptomeria japonica and of Chamaecyparis obtusa.
  • the polypeptides, salts thereof or pharmaceutical formulations of the invention may be screened in panels of Japanese Cedar pollen and/or Japanese Cypress pollen allergic individuals to confirm their suitability for use.
  • the panel of Japanese Cedar pollen and/or Japanese Cypress pollen allergic individuals may comprise individuals known or not known to be allergic to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • multiple polypeptides are provided in combination in a pharmaceutical formulation, they may be screened for their ability to cause T cell proliferation or cytokine production in at least 20 % of samples of T cells, wherein each sample is obtained from different Japanese Cedar pollen and/or Japanese Cypress pollen allergic individuals in the population.
  • the pharmaceutical formulation will induce T cell proliferation or cytokines in at least 30 % of samples of T cells obtained from of a panel of Japanese Cedar pollen and/or Japanese Cypress pollen allergic individuals. More preferably, the pharmaceutical formulation will induce T cell proliferation or cytokines in 35% or more, 40 % or more, 50 % or more, 60 % or more, 70% or more, 80 % or more, or 90 % or more of samples in the panel.
  • the number of individuals in a panel of Japanese Cedar pollen and/or Japanese Cypress pollen allergic individuals may be any number greater than one, for example at least 2, 3, 5, 10, 15, 20, 30, 50, 80, or at least 100 individuals.
  • polypeptides, salts thereof and pharmaceutical formulations of the invention cause T cell proliferation and/or cytokine production, but do not lead to the release of histamine from samples from a sensitised individual.
  • the histamine release profile of a polypeptide, salt thereof or pharmaceutical formulation may thus be confirmed.
  • Suitable samples include whole blood, enriched basophils or mast cell preparations. There may be some histamine release, but preferably the amounts released are not significant.
  • Significant histamine release may be considered to be the release of 20% or more of the total available histamine when a sample from an individual is stimulated with a pharmaceutical formulation in vitro.
  • pharmaceutical formulation of the invention preferably causes the release of less than 15%), less than 10%>, less than 5%, less than 4%, less than 3%, less than 2% or less than 1%) of the total available histamine when a sample from an individual is stimulated with a composition in vitro.
  • a normal individual typically has an approximate leukocyte histamine content of 150 ng/10 7 cells.
  • polypeptide or salt thereof described herein may be provided to an individual in an isolated, substantially isolated, purified or substantially purified form.
  • a polypeptide or salt thereof described herein may be provided to an individual substantially free from other polypeptides or salts thereof. Whilst it may be possible for the polypeptides or salts thereof to be presented in raw form, it is preferable to present them as a pharmaceutical formulation.
  • the invention further provides a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier or diluent and the polypeptides of (a) to (c) described herein or pharmaceutically acceptable salts thereof.
  • a pharmaceutical formulation comprising a combination of polypeptides or salts thereof as described above, and a pharmaceutically acceptable carrier or diluent.
  • the carrier(s) or diluent(s) present in the pharmaceutical formulation must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • carriers for injection, and the final formulation are sterile and pyrogen free.
  • the carrier or diluent is water.
  • a pharmaceutically acceptable carrier or diluent may comprise as one of its components thioglycerol or thioanisole.
  • a composition containing one or more polypeptides or salts thereof described herein can be combined with one or more pharmaceutically acceptable excipients or vehicles to produce a pharmaceutical formulation.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like, may be present in the excipient or vehicle.
  • excipients, vehicles and auxiliary substances are generally pharmaceutical agents that do not induce an immune response in the individual receiving the composition, and which may be administered without undue toxicity.
  • Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol, thioglycerol and ethanol.
  • compositions can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
  • mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like
  • organic acids such as acetates, propionates, malonates, benzoates, and the like.
  • the polypeptides or salts thereof are typically present at 0.1% to 50% by weight in the pharmaceutical formulation, more preferably at 0.1% to 5% by weight.
  • the polypeptides or salts thereof may be present at less than 0.1% by weight in the pharmaceutical formulation.
  • the pharmaceutically acceptable carrier or diluent is typically present at 50% to
  • the pharmaceutically acceptable carrier or diluents may be present at more than 99.9%) by weight in the pharmaceutical formulation.
  • compositions include, but are not limited to pharmaceutically acceptable solutions, lyophili sates, suspensions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such pharmaceutical formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • lyophilisate may comprise one or more of trehalose, thioglycerol and thioanisole.
  • the active ingredient is provided in dry form (e.g., a lyophilisate, powder or granules) for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted pharmaceutical formulation.
  • the pharmaceutical formulations may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
  • This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
  • Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3 -butane diol, for example.
  • Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono-or di-glycerides.
  • parenterally-administrable pharmaceutical formulations which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems.
  • compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
  • the polypeptides of the present invention may be encapsulated, adsorbed to, or associated with, particulate carriers.
  • suitable particulate carriers include those derived from polymethyl methacrylate polymers, as well as PLG microparticles derived from poly(lactides) and poly(lactide-co-glycolides). See, e.g., Jeffery et al. (1993) Pharm. Res. 10:362-368.
  • Other particulate systems and polymers can also be used, for example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules.
  • the formulation of any of the polypeptides mentioned herein will depend upon factors such as the nature of the polypeptide and the method of delivery.
  • the pharmaceutical formulation may be administered in a variety of dosage forms. It may be administered orally (e.g. as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules), topically, parenterally, subcutaneously, by inhalation, intravenously, intramuscularly, intralymphatically (such as to lymph nodes in the groin), intrasternally, transdermally, intradermally, epidermally, sublingually, intranasally, buccally or by infusion techniques.
  • the administration may be intratonsillar.
  • the administration may be as suppositories.
  • the administration may be made by
  • the administration is intradermal, epidermal or transdermal.
  • the administration may be made by a patch, such as a microtine patch.
  • a physician will be able to determine the required route and means of administration for each particular individual.
  • the pharmaceutical formulations of the invention are preferably provided sealed in a container.
  • the pharmaceutical formulations are typically provided in unit dose form, for example single dose form. They may alternatively be provided in multi-dose form.
  • the pharmaceutical formulation is a pharmaceutically acceptable solution
  • the solution may be provided in an ampoule, sealed vial, syringe, cartridge, flexible bag or glass bottle.
  • the pharmaceutical formulation is a lyophilisate, it is preferably provided in a sealed vial.
  • the pharmaceutical formulations of the invention will comprise a suitable concentration of each polypeptide to be effective without causing adverse reaction.
  • the pharmaceutical formulation is for example a lyophilisate
  • the relevant concentration will be that of each polypeptide following reconstitution.
  • the concentration of each polypeptide in the pharmaceutical formulation when in solution will be in the range of 0.03 to 200 nmol/ml.
  • the concentration of each polypeptide may be more preferably in the range of 0.3 to 200 nmol/ml, 3 to 180 nmol/ml, 5 to 160 nmol/ml, 10 to 150 nmol/ml, 50 to 200 nmol/ml or 30 to 120 nmol/ml, for example about 100 nmol/ml.
  • the pharmaceutical formulation should have a purity of greater than 95% or 98% or a purity of at least 99%.
  • An adjuvant or further therapeutic agent may be used in combination with one or more polypeptides of the invention.
  • An adjuvant is preferably administered in an amount which is sufficient to augment the effect of the polypeptide(s) of the invention or vice versa.
  • the adjuvant or further therapeutic agent may be an agent that potentiates the effects of a polypeptide of the invention.
  • the further therapeutic agent may be an immunomodulatory molecule which enhances the response to the
  • Non-limiting examples of adjuvants include vitamin D, rapamycin and glucocorticoid steroids such as dexamethasone, fluticasone, budesonide, mometasone, beclomethasone, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, betamethasone and triamcinolone.
  • a preferred glucocorticoid is dexamethasone.
  • the other therapeutic agents or adjuvants may be administered separately, simultaneously or sequentially. They may be administered in the same or different pharmaceutical formulations.
  • a pharmaceutical formulation may therefore be prepared which comprises a polypeptide of the invention and also one or more other therapeutic agents or adjuvants.
  • a pharmaceutical formulation of the invention may alternatively be used simultaneously, sequentially or separately with one or more other therapeutic compositions as part of a combined treatment. Accordingly, in a method of preventing or treating allergy according to the invention as described below, the subject may also be treated with a further therapeutic agent.
  • a polypeptide or salt thereof of the invention is to be administered to an individual in a pharmaceutical formulation
  • the pharmaceutical formulations of the invention can be delivered to a subject in vivo using a variety of known routes and techniques.
  • a pharmaceutical formulation can be provided as an injectable solution, suspension or emulsion and administered via parenteral, subcutaneous, epidermal, intradermal, intramuscular, intralymphatic, intraarterial, intraperitoneal, or intravenous injection using a conventional needle and syringe, a microneedle and syringe or using a liquid jet injection system.
  • the administration may be made using a patch, such as a microtine patch.
  • Compositions can also be administered topically to skin or mucosal tissue, such as nasally, intratonsillarly, intratracheally, intestinal, rectally or vaginally, or provided as a finely divided spray suitable for respiratory or pulmonary
  • administration Other modes of administration include oral administration,
  • Administration of the polypeptides, salts thereof or pharmaceutical formulations of the invention may be by any suitable method as described above. Suitable amounts of the polypeptides or salts thereof to be administered may be determined empirically, but typically are in the range given below. A single administration of each polypeptide or salt thereof may be sufficient to have a beneficial effect for the patient, but it will be appreciated that it may be beneficial if the polypeptide or salt thereof is administered more than once, in which case typical administration regimes may be, for example, once or twice a week for 2-4 weeks every 6 months, or once a day for a week every four to six months. As will be appreciated, each polypeptide or salt thereof in a combination of polypeptides or salts thereof may be administered to a patient singly or in combination.
  • Suitable doses of a polypeptide or salt thereof of the invention may be in the order of up to 10 ⁇ g, up to 15 ⁇ g, up to 20 ⁇ g, up to 25 ⁇ g, up to 30 ⁇ g, up to 50 ⁇ g, up to 100 ⁇ g, up to 500 ⁇ g or more per administration. Suitable doses may be less than 15 ⁇ g, but at least lng, or at least 2ng, or at least 5ng, or at least 50ng, or least lOOng, or at least 500ng, or at least ⁇ g, or at least 10 ⁇ g.
  • the dose used may be higher, for example, up to 1 mg, up to 2 mg, up to 3 mg, up to 4 mg, up to 5 mg or higher.
  • Doses may be provided in a liquid formulation, at a concentration suitable to allow an appropriate volume for administration by the selected route. It will be understood that the above doses refer to total dose in the case of a combination of peptides or salts thereof. For example, “up to 35 ⁇ ' refers to a total peptide or peptide salt concentration of up to 35 ⁇ g in a composition comprising a combination or more than one peptide or salt thereof.
  • the polypeptide of the invention may be administered directly, or may be administered indirectly by expression from an encoding sequence.
  • a polynucleotide may be provided that encodes a polypeptide of the invention.
  • a polypeptide of the invention may thus be produced from or delivered in the form of a polynucleotide which encodes, and is capable of expressing, it. Any reference herein to the use, delivery or administration of a peptide of the invention is intended to include the indirect use, delivery or administration of such a peptide via expression from a polynucleotide that encodes it.
  • the invention provides for example a polynucleotide which encodes a polypeptide comprising, consisting or consisting essentially of the amino acid sequence of SEQ ID NO: 5 or a variant derived from either therefrom.
  • a polynucleotide encoding a polypeptide comprising, consisting or consisting essentially of the amino acid sequence of SEQ ID NOs: 165, 54, 159, 13, 166, 23, 24 or a variant derived from any therefrom is also provided.
  • a number of polynucleotide sequences each separately encoding for a polypeptide to be expressed may be provided together in a single nucleic acid molecule or vector to allow for expression of a combination of different polypeptides from a single nucleic acid molecule.
  • the polynucleotide sequences may be expressed in a cell as a single polypeptide.
  • nucleic acid molecule and “polynucleotide” are used
  • polynucleotides include a gene, a gene fragment, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
  • mRNA messenger RNA
  • cDNA messenger RNA
  • recombinant polynucleotides plasmids
  • vectors isolated DNA of any sequence
  • isolated RNA of any sequence nucleic acid probes, and primers.
  • a polynucleotide may be provided in isolated or purified form.
  • Polynucleotides can be synthesised according to methods well known in the art, as described by way of example in Sambrook et al (1989, Molecular Cloning - a laboratory manual; Cold Spring Harbor Press).
  • polynucleotides may be used in vitro, ex vivo or in vivo in the production of a polypeptide of the invention.
  • Such polynucleotides may be
  • nucleic acid molecule can be introduced directly into the recipient subject, such as by standard intramuscular or intradermal injection; transdermal particle delivery; inhalation; topically, or by oral, intranasal or mucosal modes of administration.
  • the molecule alternatively can be introduced ex vivo into cells that have been removed from a subject.
  • a polynucleotide, expression cassette or vector of the invention may be introduced into APCs of an individual ex vivo.
  • nucleic acid vaccines Antigen presenting cells
  • the invention encompasses the use in vitro of a method of producing a population of APCs that present a polypeptide of the invention on their surface. Said population of APCs may be subsequently used in therapy. Said method of production may be carried out ex vivo on a sample of cells that have been obtained from a patient.
  • the APCs produced in this way therefore form a pharmaceutical agent that can be used in the treatment or prevention of allergy to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • the cells should be accepted by the immune system of the individual because they derive from that individual. Delivery of cells that have been produced in this way to the individual from whom they were originally obtained, thus forms a therapeutic embodiment of the invention.
  • an APC is to be administered, it is preferred to administer the APC to a site in the body where it will have the ability to contact, and activate, suitable T cells of the individual.
  • In vitro method In vitro method
  • the invention further provides an in vitro method of determining whether T cells recognize a polypeptide or salt thereof of the invention, or a polypeptide or salt thereof of a pharmaceutical formulation of the invention comprising at least three polypeptides, which method comprises contacting said T cells with said polypeptide or salt thereof or said pharmaceutical compositions and detecting whether said T cells are stimulated by said polypeptide or salt thereof.
  • the method may comprise use of a polypeptide, or salt thereof, comprising, consisting or consisting essentially of the amino acid sequence of SEQ ID NO: 5 or a variant derived therefrom.
  • the method may alternatively or additionally comprise use of a polypeptide or salt thereof comprising, consisting or consisting essentially of the amino acid sequence of any one of SEQ ID NOs: 165, 54, 159, 13, 166, 23, 24 or a variant derived from any therefrom.
  • the above method may be carried out to determine whether an individual has, or is at risk of having, an allergy to Japanese Cedar pollen and/or Japanese Cypress pollen.
  • the aim of this study is to identify a distinct panel of polypeptides having sequences with strong affinities for the seven most common human MHC class-II HLA- DRB1 * allotypes.
  • EpiMatrix is a matrix-based algorithm that ranks 10 amino acid long segments, overlapping by 9 amino acids, from any polypeptide sequence by estimated probability of binding to each of the selected MHC molecules.
  • the procedure for developing matrix motifs was published by Schafer et al, 16 Vaccine 1998 (1998).
  • binding potential for HLA DR1, DR2, DR3, DR4, DR7, DR8, DR11, DR13 and DR15 is assessed.
  • Putative MHC ligands are selected by scoring each 10-mer frame in a polypeptide sequence. This score is derived by comparing the sequence of the 10-mer to the matrix of 10 amino acid sequences known to bind to each MHC allele.
  • Estimated probability of binding to a selected MHC molecule is calculated by EpiMatrix as follows.
  • the polypeptides having a given sequence are scored by estimating the relative promotion or inhibition of binding for each amino acid, compared to known MHC binders for a given MHC allele. This information is summed across the polypeptide and a summary score (EMX score) is assigned to the entire polypeptide. After comparing the EMX score to the scores of known MHC ligands, EpiMatrix arrives at an "estimated binding probability" (abbreviated as EBP, but not strictly a probability).
  • EBP estimates the proportion of polypeptides with
  • EpiMatrix scores as high or higher that will bind to a given MHC molecule. EBPs range from 100% (highly likely to bind) to less than 1% (very unlikely to bind).
  • EpiMatrix analyses were performed on the entire sequence of known isoforms of Cry j 1 (NCBI GI accession nos: 19570317, 493632, 493634). These analyses identified core polypeptides (and their flanking sequences) derived from the above sequence which are predicted to have good MHC class-II binding. The sequences are shown below in Table 1 and were identified as being present in one or more of the isoforms.
  • the Epimatrix analysis further identified the peptides LKIKLRRTI (SEQ ID NO: 134) and IKLRRTIEA (SEQ ID NO: 135) as having binding potential for four or more HLA alleles.
  • SEQ ID NO: 134 The Epimatrix analysis further identified the peptides LKIKLRRTI (SEQ ID NO: 134) and IKLRRTIEA (SEQ ID NO: 135) as having binding potential for four or more HLA alleles.
  • Table 8 The sequences set out in Table 8 were selected by the inventors as having desirable characteristics. The selection was made based on the analyses performed in Examples 1 to 7, on homology with sequences identified in Examples 1 to 7 and/or a consideration of solubility and other physicochemical characteristics. Further sequences were selected based on analysis of additional epitope regions in the allergens of Examples 1 to 7. Polypeptides consisting of the sequences of Table 8 were particularly preferred for screening in subsequent assays. Table 8
  • the assay employed is a competitive MHC class II binding assay, wherein each polypeptide is analysed for its ability to displace a known control binder from each of the human MHC class II allotypes investigated.
  • the allotypes and control polypeptides used in this study are those shown below in Table 9:
  • Each polypeptide is analysed in the competition assay and screened for relative binding compared to the control polypeptides. Due to the nature of the competitive assay the data for each polypeptide is determined as a ratio of its own IC50 to that of the control polypeptide. Thus, a polypeptide that has an IC50 value that is parity to the control polypeptide has an identical binding affinity, while peptides with a ratio less than one have a higher affinity and those with a ratio greater than one have a lower affinity.
  • Solubility in aqueous solution is an essential criterion for a polypeptide to be an effective therapeutic agent. Therefore, as a consequence of the solubility screen very hydrophobic polypeptides with a high frequency of large hydrophobic amino acid residues in multiple binding registers will be eliminated. This is a characteristic of promiscuous HLA-DRB 1 * binders. Polypeptides which bind to one or more of the MHC Class II allotypes are identified. It would be expected that such polypeptides would have the ability to bind similar allotypes that have not been tested through the homology of MHC structures. Example 10
  • a cell proliferation assay was performed on PBMCs (0.5 xlO 6 cells per test well). Proliferation was measured by the incorporation of the radiolabelled compound 3H-thymidine.
  • ⁇ of the positive control whole Japanese Cedar pollen allergen extract 200 ⁇ g/ml or Candida Albicans (20ug/ml) or polypeptide (200 ⁇ g/ml) was distributed into the appropriate wells of 96 well plates. Plates were prepared in advance and stored at -20°C prior to the day of assay.
  • PBMCs isolated as described below were prepared to a concentration of 5x10 6 cells/ml in complete medium at room temperature. ⁇ of cell solution was then distributed into each of the wells of the 96 well plates containing
  • the plates were then incubated for 6 days into a humidified 5%C02 incubator set at 37°C.
  • the cultures were pulsed with tritiated thymidine solution by adding ⁇ of tritiated thymidine stock solution (1.85MBq/ml in serum-free RPMI medium) to each well.
  • the plates were then returned to the incubator for between 16 and 20 hours. Cultures were then harvested using a cell harvester. Dried filter mats were counted using an appropriate beta scintillation counter.
  • SI Stimulation Index
  • a positive result was taken as a SI greater than the SI of the average of wells containing media alone +/- 3* standard deviation (probability >99%).
  • the number of responders out of 50 Japanese Cedar pollen allergic subjects tested was calculated for each polypeptide.
  • Polypeptides for use in this assay were manufactured at small scale
  • each polypeptide was at least 95% by HPLC.
  • 96 well culture plates containing polypeptides and controls were prepared in advance and stored at -20°C prior to the day of assay. Polypeptides were added to wells in a volume of 100 ⁇ containing polypeptides at a concentration of 200 ⁇ g/ml, such that subsequent addition of 100 ⁇ of cells would create a final assay concentration of 100 ⁇ g/ml.
  • PBMCs Peripheral blood mononuclear cells
  • cytokine bead assays IL-10, IL-13, Interferon gamma (IFN-g)
  • Single measurements were performed for each culture supernatant sample.
  • individual cytokine levels were determined by interpolation from the standard curve generated in the assay.
  • a positive result was taken as a cytokine release greater than the mean +/- 3* standard deviations of the background cytokine release (probability >99%).
  • the number of responders out of 50 Japanese Cedar pollen allergic subjects tested was calculated for each polypeptide for each of the cytokines.
  • polypeptides identified in Example 10 as eliciting cytokine and proliferative responses in Japanese Cedar allergic subjects were analysed for their pharmaceutical development characteristics.
  • Peptides determined to have particularly suitable cytokine and/or proliferative responses and pharmaceutical development characteristics included CRY04, CRY08, CRY10A, CRY11, CRY 14, CRY 15 A, CRY 16, CRY 17, CRY18, CRY 19, CRY 19 A, CRY21, CRY22, CRY23 and CRY26.
  • Solubility was identified as needing to be improved for peptides CRY11, CRY 17 and CRY21.
  • Variants CRY1 IB, CRY11C, CRY1 ID, CRY1 IE, CRY1 IF, CRY 17 A, CRY17B, CRY21 A, CRY21B and CRY21C shown in Table 10 below were designed accordingly.
  • the variants were tested for solubility in multiple buffers with variants CRY1 IF , CRY17A and CRY21C being the most soluble in multiple buffers (water; 2mM HC1, lOmM glycine (pH 3); lOmM phosphate (pH4); and 10 mM succinate (pH 4)).
  • Truncation of the CRY11 N-terminus was found to significantly improve solubility while maintaining activity (see results below).
  • Variant polypeptides from Example 11 were tested in a histamine release assay alongside other top performing peptides.
  • the purpose of this assay was to identify peptides capable of activating blood basophils (as a surrogate for tissue mast cells) resulting in histamine release that may result in allergic reactions during therapy.
  • a composition comprising peptides that induce histamine release frequently may be considered unsuitable for use as a vaccine.
  • Histamine release requires the crosslinking of adjacent specific IgE molecules on the surface of the basophil.
  • the peptides being evaluated were relatively short (11 to 18 amino acids in length) and should not, therefore, possess significant tertiary structure that would enable them to retain the conformation of an IgE-binding epitope of the whole molecule. Furthermore, peptide monomers in solution, even if they are bound by IgE, should not be able to crosslink adjacent IgE molecules.
  • Histamine release from fresh peripheral whole blood taken from Japanese Cedar pollen allergic subjects was evaluated. Peripheral blood basophils were used as a surrogate for tissue mast cells which were not practical to assay. Blood was incubated in vitro with peptides identified as suitable based on the results of Examples 1 to 11 above. Histamine release in response to whole Japanese Cedar pollen allergen extract was measured in each subject to confirm basophil sensitisation. A positive control, representing total histamine release, generated by freeze/thawing the cells twice, was included in each assay. A negative control for spontaneous histamine release was generated by incubating cells in buffer only.
  • the assay was performed using the Immunotech Histamine Release
  • Immunoassay kit Following the in vitro challenge of blood basophils with peptide mixtures, whole allergen or buffer in microtitre plate wells, supernatants were removed and the histamine in the samples converted to acyl histamine. Acylated samples were tested by a competitive acyl histamine ELISA.
  • Peptide mixtures were assayed for their ability to induce histamine release over a 5 loglO range (1 to 10,000 ng/ml).
  • the concentration range assayed was selected based on theoretical in vivo doses of peptide that may be achieved during therapy. For example, a 31 ⁇ g dose (approximately 3 nmol/peptide equivalent) of each peptide entering a blood volume of 5 litres, would result in a blood concentration of 6ng/ml, at the lower end of the histamine release assay dose range.
  • the whole Japanese Cedar pollen allergen extract was used over the concentration range of 10 to 100,000 ng/mL.
  • Table 11 shows peptides having either no signal or a very weak signal in the histamine release assay, and thus considered very good candidates for development.
  • Variant polypeptides from Example 11 were tested in proliferation and cytokine release assays as described in Example 10 alongside other top-performing peptides using a frozen batch of the PBMCs isolated from Japanese Cedar pollen allergic subjects previously.
  • the cytokine release assay was optimized for use of PBMCs that had been frozen. Differently from the procedure described in Example 10, the PBMC were frozen after isolation and stored at -80C or liquid nitrogen vapors until the day of the assay. After thawing, the PBMC were cultured in the assay plates in complete media supplemented with human IL-7 (0.5ng/ml).
  • Results are shown in Figure 3. Highly ranked peptides based on one or more response criteria included peptides CRY19A (CHA19), CRY 15 A, CRY22, CRY23 and peptides from the CRY11, CRY17 and CRY21 series. As in Example 10, peptides from the CRY11, CRY17 and CRY15 series were amongst the top performers. .
  • peptides from the CRY11, CRY15 and CRY19 series in combination were found to be particularly effective.
  • Combining peptides CRY1 IF, CRY15A and CRY19A (CHA19) provided for 98% coverage of the trial population of allergic individuals in terms of response to at least one peptide in the combination, as shown in Figure 4A. 64% of the population showed responses to all three of the peptides in the combination.
  • a combination of three polypeptides selected one each from CRY1 ID, CRY 15 and CRY19A and variants thereof (most preferably CRY1 IF, CRY19A and CRY15A), is particularly useful for treatment or prevention of Japanese Cedar pollen and/or Japanese Cypress pollen allergy.
  • Figure 4B provides an analysis of population coverage in terms of numbers of the percentage of subjects having positive responses to each peptide by production of one, two or three of the cytokines assayed. The data show that peptides CRY22, CRY23, CRY 19 A, CRY 17 A, CRY11F, CRY15A and CRY21C are all able to provide additional population coverage over and above responses observed for other individual peptides.
  • Additional polypeptides from those in the CRY21 series, CRY17 series, CRY22, CRY23, CRY08 (and variants thereof) or from any of the other described T-cell reactive polypeptides may be added to the "core" combination of three polypeptides described above, to capture additional responses observed in the study population, and to further improve population coverage and redundancy.
  • Peptide CRY08 was found to be a particularly useful additional polypeptide alongside the "core" combination of three polypeptides described above.
  • CRY08 produced a positive cytokine response in 10 subjects that did not respond to the other cry j 1 -derived epitope and thus provides valuable redundancy by capturing subjects that do not respond to a peptide of the core combination. Additionally, adding CRY08 to the core combination increased the cumulative number of positive responses elicited by each peptide in a subject sample). Accordingly, the polypeptide CRY08 (or a variant thereof) is a preferred additional polypeptide for inclusion in polypeptide combinations described herein.
  • Peptide CRY17A was further selected as a useful additional polypeptide to be included alongside the core combination of three polypeptides discussed above.
  • Peptide CRY17A had good cytokine and proliferation response data, and additionally was shown to have useful MHC binding characteristics, as discussed below. Accordingly, the polypeptide CRY17 (or a variant thereof, most preferably CRY17A) is a preferred additional polypeptide for inclusion in polypeptide combinations described herein.
  • polypeptides are provided by five polypeptides selected one each from CRY 19 A, CRY1 ID, CRY 17, CRY15, CRY08 and variants thereof, most preferably CRY 19 A, CRY1 IF, CRY 17 A, CRY15A and CRY08.
  • Polypeptides from the CRY21 series, and CRY22 and CRY23 (and variants thereof) were further selected as additional components, as a basis for combinations of seven or eight polypeptides able to provide very high or total population coverage.
  • Polypeptides in the CRY21 series were found to have good proliferative and cytokine responses and also to capture subjects that do not respond to other preferred peptides.
  • the most-preferred peptide in the CRY21 series was CRY21C, which also had useful MHC binding characteristics, as discussed below.
  • the polypeptide CRY22 was found to have good biological activity according to both response parameters and also was a polypeptide capturing one subject (2% of the population) that did not respond to other preferred peptides.
  • polypeptide CRY23 was also found to have very good biological activity.
  • the response multiplicity score shown is the cumulative number of positive responses to each peptide in the combination for at least one cytokine.
  • the cumulative cytokine response score is the cumulative number of positive responses to each peptide in the combination for all three cytokines.
  • the mixture of the preferred five polypeptides had a high response multiplicity score and cumulative cytokine response score and provided coverage for effectively the entire population.
  • the addition of two or three polypeptides to the preferred five polypeptides advantageously improved the response multiplicity score and cumulative cytokine response score, as shown for each of Mixtures 1-4. Additionally, population coverage was further improved.
  • the most preferred peptide mixture (Mixture 4) was selected based on having the highest response multiplicity score and cumulative cytokine response score, and since it had a total population coverage, and only one subject responded to a single peptide in the combination, all others responding to two or more of the polypeptides.
  • polypeptides described above were tested in an in vitro MHC class-II binding assay.
  • the assay employed was a MHC class II binding assay (REVEAL®, Prolmmune), wherein each polypeptide was analysed for binding to MHC molecules compared to binding of a positive control peptide.
  • the allotypes and control polypeptides used in this study are shown below.
  • the panel of allotypes was selected to include 24 alleles common to supertypes presented in the Japanese population, and thus to provide further specific information on impact in the Japanese population.
  • the individual and cumulative genotype frequencies for these HLA alleles in the Japanese population are shown in Figure 9.
  • Each polypeptide was analysed in the assay for binding to each of the alleles and screened for relative binding compared to the positive control polypeptide to provide a Prolmmune REVEAL® binding score as a percentage of the signal generated by the positive control polypeptide.
  • a higher REVEAL® score is thus indicative of strong binding to the MHC molecule.
  • This binding score was calculated at 0 and 24h.
  • the signals at these time points were used to derive an approximation to a half-life based on a one-phase dissociation equation.
  • a stability index was then calculated by multiplying the approximated half-life by the Prolmmune REVEAL® score from the binding assay. A higher stability index indicates a more stable MHC-peptide complex
  • the binding assay data for all peptides against each allele was then analysed in combination with the frequency of the alleles in question in the Japanese population to provide a determination of the potential impact of each peptide in the population.
  • the binding data was renormalized by resetting the positive binding level for each allele to the level of binding representing the 98 th percentile level of all peptides where some peptides exceed the binding level of the original positive control for the allele.
  • the normalized binding data was then multiplied by the frequency of each allele in the Japanese population to obtain the percent potential impact for each peptide/allele combination. Finally, for each peptide being studied, the percent impact for every allele was added together and plotted (with the contribution provided by each allele shown in the various sections of each bar) to provide the total percent impact in the population.
  • Results for binding at 0 and 24 hours are shown graphically in Figures 6A and B with the binding scores and stability indices for the various alleles shown in Figures 7 and 8.
  • Seven out of the eight peptides of the most preferred polypeptide combination (Mixture 4, all except CRY08, which was not tested) were each demonstrated to have binding to Japanese MHC supertype alleles. The pattern of binding was generally pan- allele/supertype, and thus the peptides were promiscuous binders.
  • CRY17A was identified as having particularly useful MHC II binding characteristics since it showed the greatest pan-allele binding of all of the peptides tested.
  • Peptide CRY21C had the second greatest pan-allele binding and so also had particularly useful HLA binding characteristics.
  • peptides CRY17A and CRY21C have particular utility in a peptide combination for treating or preventing allergy to Japanese Cedar pollen in the Japanese population.
  • Peptides are prepared as follows. Synthesis is performed in a solid phase peptide synthesis (SPPS) reactor and started by suspending the substituted resin in N,N- dimethylformamide (DMF). After washing of the resin with DMF, each coupling procedure is performed by addition of the N-a-protected amino acid derivative or the N- a-protected dipeptide to the preceding amino acid in the presence of N-[(1H- Benzotriazol-l-yl)(dimethylamino)methylene]-N-methylmethanaminium
  • TBTU tetrafluorob orate N-oxide
  • DIPEA ⁇ , ⁇ -diisopropylethylamine
  • DIPEA diisopropylcarbodiimide
  • HOBt 1-hydroxybenzotriazole
  • an Fmoc-deprotection procedure is performed. It consists of washing of the resin with DMF, cleaving the Fmoc-group with 20% (V/V) piped dine in either DMF or l-Methyl-2-pyrrolidone (NMP), and subsequent washings with DMF and isopropanol (IP A). For each single step, the solvents and/or reagents are added, and the reaction mixture is stirred and then filtered to remove the solvents and/or reagents from the resin.
  • Acetate or hydrochloride salts of the specified peptides are prepared by the following methods.
  • the peptide resin is treated with cold trifluoroacetic acid (TFA) at room temperature for 1.5 to 3 hours in the presence of 1,2-ethanedithiol (EDT), triisopropylsilane (TIS), and water.
  • TFA 1,2-ethanedithiol
  • TMS triisopropylsilane
  • the product is precipitated in cold diisopropyl ether (IPE). It is then filtered off, washed with IPE, and dried under reduced pressure.
  • the product is then reconstituted and purified by high-performance liquid chromatography (UPLC).
  • UPLC high-performance liquid chromatography
  • the trifluoroacetate salt is reconstituted in 5% (V/V) aqueous acetic acid and loaded onto an ion exchange resin. The elution is performed with 5% (V/V) aqueous acetic acid. The acetate is filtered through a 0.2 ⁇ membrane filter and lyophilized to yield the final product as a white to off-white powder.
  • the trifluoroacetate salt is reconstituted in 0.01 M HCl in purified water and filtered where necessary.
  • the solution is loaded onto a preparative HPLC column for ion exchange into the hydrochloride salt.
  • the ion exchange is performed by washing the column with a 0.1 M ammonium chloride solution followed by 0.01 M HCl.
  • the hydrochloride is filtered through a 0.2 ⁇ membrane filter and lyophilized to yield the final product as a white to off-white powders.
  • Exemplary pharmaceutical formulations of the present invention contain components as set out in Table 14.
  • the peptide salt is an acetate or hydrochloride or trifluoroacetate salt.
  • the peptide CRY19A is preferably present as a hydrochloride salt.
  • Table 15 Level of des-Arg-Pro-CRY19A in CRY19A during exposure to conditions mimicking the different phases of peptide manufacturing
  • Table 16 Level of des-Arg-Pro-CRY19A fragment over time during storage of CRY19A at different temperatures and as different salts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un polypeptide ou un sel pharmaceutiquement acceptable de celui-ci et des formulations pharmaceutiques d'au moins trois polypeptides ou sels de ces derniers, peuvent être utilisés pour la prévention ou le traitement d'une allergie au pollen du cèdre du Japon et/ou du cyprès du Japon.
PCT/GB2017/050246 2016-02-02 2017-02-01 Peptides de l'allegène du pollen du japon pour la prévention ou le traitement d'une allergie Ceased WO2017134430A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1601872.3 2016-02-02
GBGB1601872.3A GB201601872D0 (en) 2016-02-02 2016-02-02 Japanese cedar and japanese cypress peptides for preventing or treating allergy

Publications (1)

Publication Number Publication Date
WO2017134430A1 true WO2017134430A1 (fr) 2017-08-10

Family

ID=55590559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2017/050246 Ceased WO2017134430A1 (fr) 2016-02-02 2017-02-01 Peptides de l'allegène du pollen du japon pour la prévention ou le traitement d'une allergie

Country Status (2)

Country Link
GB (1) GB201601872D0 (fr)
WO (1) WO2017134430A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700929A2 (fr) * 1994-09-10 1996-03-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptides dérivés de allergènes du pollen de cèdre et leur applications
EP0958834A1 (fr) * 1996-11-13 1999-11-24 Meiji Milk Products Company Limited Agent immunotherapeutique peptidique
EP0960887A1 (fr) * 1996-06-14 1999-12-01 Meiji Milk Products Company Limited PEPTIDE ANTIGENE Ly
US20050152927A1 (en) * 1991-07-12 2005-07-14 Immulogic Pharmaceutical Corp. Allergenic proteins and peptides from Japanese cedar pollen
WO2013119853A1 (fr) * 2012-02-07 2013-08-15 La Jolla Institute For Allergy And Immunology Épitopes de protéines allergènes et procédés et utilisations pour une modulation de la réponse immunitaire
WO2016209959A2 (fr) * 2015-06-22 2016-12-29 Alk-Abelló A/S Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152927A1 (en) * 1991-07-12 2005-07-14 Immulogic Pharmaceutical Corp. Allergenic proteins and peptides from Japanese cedar pollen
EP0700929A2 (fr) * 1994-09-10 1996-03-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptides dérivés de allergènes du pollen de cèdre et leur applications
EP0960887A1 (fr) * 1996-06-14 1999-12-01 Meiji Milk Products Company Limited PEPTIDE ANTIGENE Ly
EP0958834A1 (fr) * 1996-11-13 1999-11-24 Meiji Milk Products Company Limited Agent immunotherapeutique peptidique
WO2013119853A1 (fr) * 2012-02-07 2013-08-15 La Jolla Institute For Allergy And Immunology Épitopes de protéines allergènes et procédés et utilisations pour une modulation de la réponse immunitaire
WO2016209959A2 (fr) * 2015-06-22 2016-12-29 Alk-Abelló A/S Combinaisons de peptides et leur utilisation dans le traitement de l'allergie aux pollen de cèdre

Also Published As

Publication number Publication date
GB201601872D0 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
US9744222B2 (en) Peptide for vaccine
CN102170897B (zh) 用于治疗豚草变态反应的包含Amb a 1肽的疫苗
DK2536429T3 (en) Peptides for vaccines birch allergy
DK2393830T3 (en) Grass peptides for vaccine
WO2009095646A2 (fr) Peptides du facteur viii
US9850281B2 (en) Cladosporium peptides
WO2017134430A1 (fr) Peptides de l'allegène du pollen du japon pour la prévention ou le traitement d'une allergie
WO2013179043A1 (fr) Peptides d'alternaria
WO2014001820A1 (fr) Peptide de cèdre japonais pour prévenir ou traiter une allergie
AU2013203568B2 (en) Peptides for desensibilization against allergens
HK1164700B (en) Peptides for desensibilization against allergens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17704294

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17704294

Country of ref document: EP

Kind code of ref document: A1